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ABSTRACT

More than a decade into the development o f gold nanoparticles, with multiple
clinical trials underway, ongoing pre-clinical research continues towards better
understanding in vivo interactions. The goal is treatment optimization through improved
best practices. In an effort to collect information for healthcare providers enabling
informed decisions in a relevant time frame, instrumentation for real-time plasma
concentration (multi-wavelength photoplethysmography) and protocols for rapid
elemental analysis (energy dispersive X-Ray fluorescence) o f biopsied tumor tissue have
been developed in a murine model. An initial analysis, designed to demonstrate the
robust nature and utility o f the techniques, revealed that area under the bioavailability
curve (AUC) alone does not currently inform tumor accumulation with a high degree o f
accuracy (R2=0.56), marginally better than injected dose (R2=0.46). This finding
suggests that the control o f additional experimental and physiological variables (chosen
through modeling efforts) may yield more predictable tumor accumulation. Subject core
temperature, blood pressure, and tumor perfusion are evaluated relative to particle uptake
in a murine tumor model. New research efforts are also focused on adjuvant therapies
that are employed to modify circulation parameters, including the AUC, o f nanorods and
gold nanoshells. Preliminary studies demonstrated a greater than 300% increase in
average AUC using a reticuloendothelial blockade agent versus control groups. Given a
better understanding o f the relative importance o f the physiological factors that influence

rates o f tumor accumulation, a set o f experimental best practices is presented. This
dissertation outlines the experimental protocols conducted, and discusses the real-world
needs discovered and how these needs became specifications o f developed protocols.
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CHAPTER 1
INTRODUCTION

1.1

Introduction to Cancer

Cancer is a blanket term used for several different diseases and types o f conditions.
These conditions all demonstrate an uncontrolled growth and potential spread o f mutated
cells. Cancer is observed across all genders, races, and ethnicities. Approximately
1,660,290 new cancer diagnoses and approximately 580,350 deaths from cancer are
expected in the United States in 2013. This disease also carries a cost (in 2008) o f $77.4
billion in medical costs and $124 billion in lost productivity. [1] Estimations based on
current cancer research and clinical trials suggest that by the year 2022 the number o f
cancer survivors will increase from 13.7 million Americans in 2012 to around 18 million
Americans. [2]
The nature o f most tumors suggest that there is a problem in the regulations o f tumorsuppressor genes, oncogenes and/or the apoptosis regulators. It is believed that it takes
multiple mutations o f the oncogenes and tumor-suppressor genes to result in malignant
tumor. [3] Cancer cells demonstrate changes that lead to a defect in the normal regulatory
systems o f cell proliferation and homeostasis. [4] These problems with the cell
proliferation and homeostasis are connected with a problem with the two pathways o f
apoptosis (Stress pathway, and death receptor pathway). [3]
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Solid tumors account for approximately 85% o f cancers, and are the subject o f a
large international research effort. [5] The successful outcome o f tumor treatments often
depends on physicians’ experience and available techniques. [6], [7] Survival rates have
improved over the past few decades with a one-year’s survival rate going from 69.9% in
1975 to 81.8% in 2008, and a 10 year survival rate going from 41.9% in 1975 to 60.6% in
1999. [1], [2], [8] Tumors that are surgically accessible are removed. If surgical removal
is not feasible, which can be the case for tumors that lie near sensitive tissues, such as
head, neck, and brain, or those that have metastasized, often fall within the domain o f
radiation or chemotherapy. [9] Chemotherapy involves injecting an inherently toxic
substance [10] and relies on the high metabolic activity o f malignant cells to quickly
absorb the chemotherapeutic agent. However, the uptake and retention o f traditional
chemotherapeutic small/macro-molecules can be hindered by abnormal blood and
interstitial fluid pressures (IFP) in the tumors [11] and thus, even less systemically toxic
agents (such as Herceptin), developed in recent years [12], can cause significant side
effects.
Identified at least thirty years ago, the anatomical and physiological
characteristics o f tumors underwent much study in the 1980s [13], [14] and 1990s [15],
but since these characteristics vary with tumor size, type, and location [16], [17],
quantifying usable metrics to inform drug and nanoparticle design have been elusive.
Although early empirical studies have identified the particle’s size that provides
substantial improvement over the weak uptake observed with macromolecules in some
tumors [18], these studies are not general in form and do not necessarily apply to other
particles or conditions.
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Sensing and imaging technologies that are capable o f quantitatively characterizing
the scale o f nanoparticles have enabled the development o f the first round o f nanomedical
technologies at an experimental or prototype level. An examination o f the literature and
interaction with various companies currently involved in clinical trials suggest that the
variability in the quality control o f the manufacture, storage, and experimental protocols
make comparisons difficult. [19]
Some o f the nanomaterials currently found in the market for cancer therapies are
nanocarrier-based drugs. A few examples are Zinostatin, Stimalmer, Oncaspar, Ontak,
Zevalin, Bexxar, Myocet, and Abraxane. These carriers include protein conjugates,
immunoconjugates, and liposomes. [20] Additional types o f nanomaterials, such as
Auroshells and Combidex, are currently undergoing clinical trials. These particles are
gold nanoshells and iron oxide nanoparticles, respectively. [21] Gold nanoshells and
nanorods have unique optical properties that allow for non-invasive, real-time monitoring
o f nanoparticle concentration in the blood. [22]—[24] However, whatever type o f
nanoparticle is chosen, o f key importance in nanoparticle-based cancer treatment is the
exploitation o f the natural differences between cancerous and healthy tissue for the
selective delivery to tumor cells in order to reduce damage to healthy cells. Indeed, some
tumors present a unique physiology that distinguishes them from healthy tissue; in
particular, they are characterized by an abnormal vasculature and the lack o f functioning
lymphatic vessels. [14] Studies have demonstrated that the vasculature o f some tumors is
quantifiably different from normal tissue in the lack o f a complete basement membrane,
abnormally large interendothelial junctions, permeability, and size [5], [14] and these
differences are commonly exploited for passive delivery via the enhanced permeability
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and retention effect (EPR). For example, the average pore cutoff size in tumors is much
larger (380-780 nm dia. [15]) than for normal blood vessels (10-20 nm dia. [25]) and
thus larger nanoparticles will be selectively absorbed in tumors over healthy tissue.
However, some other characteristics o f tumor tissue, such as higher 1FP than normal
tissue [26], lead to a less efficient delivery. Thus, a careful study o f all these factors is
important in order to take better advantage o f those properties resulting in an increased
delivery while minimizing the effect o f those that would make the delivery less effective.

1.2

Nanoparticles in Development for Cancer Therapies

Several types o f nanomaterials are currently under investigation in multiple stages o f
preclinical and clinical trials for use in cancer therapies. Some o f these nanomaterials
include liposomes and micelles (Doxil/Caelyx), polymer (Oncaspar), iron oxide
(NanoTherm), and gold nanoshells (Auroshell). [21] The nanomaterials are used due to
the ability to engineer specific characteristics to target tumors. Nanomaterials either
actively (by attaching molecules that bind to antigens or receptors on target cells) or
passively (by exploiting EPR) accumulate in tumor tissue. [20]
The EPR effect is a commonly found defect in the vessel walls o f tumors. As tumors
rapidly grow the need for nutrients is significant, as a result healthy vasculature is unable
to keep up with the constant demand for more nutrients. The expansion o f the vasculature
toward the tumor is supported by vascular endothelial growth factor and basic fibroblast
growth factor. An imbalance in the pro- and anti- growth factors leads to poorly regulated
expansion o f the vasculature. This lack o f oversight leads to poorly formed vessels and
defective basement architecture allowing larger particles and molecules to escape the
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vasculature in these areas. These larger particles are not able to escape the well-formed
(healthy or non-tumorous) vasculature. [27]
1.2.1

Active vs. Passive Tumor Targeting

1.2.1.1

Passive Targeting

Passive tumor targeting involves the EPR effect. This effect in combination with the
poor lymphatic drainage creates an environment where specifically sized particles can
preferentially accumulate, compared to normal tissue. This specific set o f conditions is a
result o f the rapid angiogenesis necessary for the rapid and unchecked growth o f tumor
tissue. Research suggests that taking advantage o f these factors alone particles up to
approximately 400 nm are able to extravagate, but particles under 200 nm are most
effective. [20] A model suggested that the pore size is more important than the particle
size for effective extravasation. [28] Pore size (a factor in perfusion) can be modified by
several methods including hyperthermia. [28], [29] Once in the target tissue the particle
would complete an action it is designed to do, such as heat when energy (light or
magnetic) is applied or release a chemotherapeutic agent.
1.2.1.2

Active Tarzetins

The purpose o f active targeting is to avoid problems, such as poor perfusion, by
designing particles to bind to specific cells after extravasation from the vasculature. This
is typically done by attaching targeting agents (generally classified as proteins, nucleic
acids, or receptor ligands) to the surface o f the particle. These agents must be highly
specific to the target tissue type, or the particle would complete its action on an undesired
tissue. Some particles have such a high binding affinity that they have lost some
penetration depth. [20] Active targeting techniques using surface modifications to gold
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nanorods have demonstrated a small improvement compared to passive accumulated
control groups. [30] This result brings up questions regarding the utility o f active
targeting and the importance o f perfusion and injection route (regardless o f targeting) in
accumulation.
1.2.2

Types o f Nanoparticles

1.2.2.1

Liposomes

Liposomes are spherical and made o f a lipid bilayer, creating a core area potentially
used for encapsulation o f drugs. This method is advantageous due to the ability o f the
liposomes to preferentially accumulate in tumors due to the EPR effect. The preferential
accumulation in tumors allows the chemotherapeutic agent in the liposome to be given in
lower doses, and be less systemically toxic while retaining the desired toxicity and
concentration in the target tumor. Liposomes also allow for the manipulation o f
properties such as size, drug release rate, bioavailability, and dosing schedule can
increase efficacy while lowering damage to other tissues. The United States FDA first
approved this type o f therapeutic agent in 1990 as DOXIL (liposomal doxorubicin). [31 ]
1.2.2.2

Hvdroeel

Hydrogels are network o f cross-linked polymer chains that are hydrophilic and
commonly used as tissue scaffolds. Several studies have been and are being conducted
using cross-linkers that will degrade under specific conditions, usually to release an
encapsulated drug. Tauro and colleagues have demonstrated potential use o f
poiy(ethylene glycol) diacrylate (PEGDA) hydrogel nanoparticies to deliver
chemotherapeutic agents to highly specific sites, and for use in treatment o f glioblastoma.
[32]
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1.2.2.3

Polymer

Polymeric nanoparticies are developed and are similar in nature to the hydrogel
nanoparticies. In the same way as hydrogel nanoparticies, the polymeric nanoparticies are
being made from erodible polymers so when they erode they release an encapsulated
drug and then disappear. Poly(s-caprolactone), poly(lactic acid), poly(g!ycolic acid) and
their copolymers are among the polymers under heavy investigation for use in cancer
therapies. Research on these nanoparticies is focusing on “smart” technologies, which
similarly to hydrogel nanoparticies, are sensitive to environmental stimuli. Some particles
will have active targeting toward a specific site and some will be passive targeting, but
triggered by site-specific conditions to release the encapsulated drug. Active targeting
will involve ligands and aptamers, and site triggering could focus on pH or thermo
response. In addition, some particles could be produced with multiple “smart”
technologies. The use o f polymeric nanoparticies could help in the location specific
delivery o f chemotherapeutic agents, decreasing systemic toxicity and improving patient
outcomes. [33]
1.2.2.4

Iron Oxide

Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticies have been evaluated
for use as an enhancement for magnetic resonance imaging (MRI). This contrast agent
would provide information to assist in the staging o f axillary lymph nodes in breast
cancer patients. The Dextran-coated USPIOs demonstrated a half-life o f 36 hours. The
use as a contrast agent due to uptake in normal lymph node macrophages and a lack o f
uptake in tumor cells. [34]
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1.2.2.5

Gold Nanoshells / Nanorods

Gold nanoshells are spherical particles with a dieletric core with a thin gold shell. The
ratio o f core to coating gives the nanoshell’s tunable optical properties. [35] Gold
nanoshells (diameter o f approximately 155 nm) and nanorods (14 x 45 nm) have
demonstrated utility in cancer therapies through the use o f the tunable optical properties.
One therapy involves the intravenous injection o f gold nanoparticies and passive
accumulation in tumor tissue. Once accumulation is complete the particles are exposed to
a specific wavelength o f light (by fiber optic), which excites and heats the nanoparticies,
killing the tumor. This photothermal ablation o f the tumor has, two major advantages:
killing the tumor along vascular lines (cutting the tumor o ff from its source o f nutrients)
and preferentially killing the tumor minimizing damage to healthy tissue surrounding the
tumor. Once the tumor dies, the cells are disposed o f by the immune system. [35]—[38]

1.3

Research Need & Presented Research

A goal for this research is to discover needs, and create specifications driven
research to solve problems in pre-clinical and clinical implementation o f gold
nanoparticle driven therapies. This research is designed to answer questions about the use
o f gold nanoparticies that are applicable to clinical trials in the future. The results o f each
unique experiment will be used to construct a standard one compartment pharmacokinetic
model. The use o f near real-time pharmacokinetics will give us a unique and faster look
at the physiological response to nanoparticies, giving us the ability to more rapidly make
recommendations on treatments. Through these experiments, we will work to use
pharmacokinetic parameters and models to make recommendations and create a set o f
“best” practices in cancer nanomedicine. These “best” practices should include a set o f
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standardized guidelines and specifications (shown in Table 1-1) to help in the design and
use o f nanomaterials and implementation o f near real-time pharmacokinetics.

Table 1-1: Real-world needs found during experimentation and design specifications o f
implemented solutions.

Reliable Review of Data Quality

Save data for offline analysis

Uniform Data Output

MATLAB code for data
quality review and creation of
graphs and PK metrics

Loss of high quality pulsatile
signal

Prevent loss of peripheral
circulation by discontinuing
anesthesia and keep animal in
warm ambient environment

Ability for Rapid Blood Plasma
Concentration Reading

Less than 5 minutes

NP Stains on Tail Interfere With
NanoTracker Readings

Injection rate set to
<18pL/min

Tumor Uptake Data in Clinically
Relevant Time Frame

Analyzed in less than 12 hrs.

Minimal Sample Prep for
Elemental Analysis

Minimize "skilled" tasks to
pipetting

Extended Circulation
Nanoparticies

4-48 hr. maximum
concentration in tumor

PK Metrics did not predict
uptake

Quantify additional
potentially important
variables

Large Variation in maximum
blood plasma concentration

Achieve ±10% of injection
goal with 95% precision

The body o f research presented in this dissertation is the product o f iterative and
tangential improvements to rapidly develop protocols for use in translational pre-clinical
trials using gold nanoshells and nanorods in conjunction with clinical trials on gold

nanoshells. The flow o f these experiments is shown in Figure 1-1, and the evolving list o f
real-world needs and design specifications.

Protocol
Review:

U*t of Real-Tim*
Phatmacokinst-

Hyperthermia and
Long vs Short

Initial Experiments

ict

Energy
Dispersive
X-Ray
Fluorescence
U n of Reel-Time

Pharmacokinetics
Revised Experi
ments

Mathematical
Modeling:
Monti C a rlo

Mathematical
Modeling:

RES Blockade
and Redosing

Controls

Observations of
Cofactors on
Preaction of
Uptake

Injection
Normalization

Figure 1-1: Flowchart to visualize experimental development.

The work started with a review o f the standing pre-clinical protocols to
familiarize researchers with the protocols and make observations o f improvements
(CHAPTER 4: Animal Protocol Review Using Gold Nanoshells). The recommendations
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from this review were integrated into the work o f both iterations o f CHAPTER 6: Use o f
Real-Time Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods. The initial
experiments o f CHAPTER 6: Use o f Real-Time Pharmacokinetics to Predict Tumor
Uptake o f Gold Nanorods revealed a need to develop a rapid elemental analysis system to
be able to observe a full set o f data on one animal prior to the beginning o f an experiment
on another animal (and for future clinical work). This need for a rapid elemental analysis
system lead to the work in CHAPTER 5: Development o f an Energy Dispersive X-Ray
Fluorescence (EDXRF) Technique for Elemental Analysis o f Gold Nanorods, and this
novel rapid elemental analysis technique was used in the revised experiments o f
CHAPTER 6: Use o f Real-Time Pharmacokinetics to Predict Tumor Uptake o f Gold
Nanorods. The data from these revised experiments was used in three unique paths:
1) Can a control feedback system be created to control the injection phase?
(Section 3.2: Mathematical Modeling- Controls)
2) Can adjuvant therapies affect the circulation pattern o f nanorods during the
accumulation phase? (CHAPTER 8: Reticuloendothelial System Blockade
and Redosing o f Gold Nanorods in a Murine Model)
3) This data set was used as experimental data for the confirmation o f the Monte
Carlo model presented in section 3.1: Mathematical Modeling- Monte Carlo.
The Monte Carlo model presented in section 3.1 suggested some parameters (pore
size, particle size, blood plasma concentration o f NPs, and blood pressure) o f the model
could affect the delivery o f NPs to a solid tumor. Some o f these parameters became the
focus o f our next study: CHAPTER 7: Observation o f Cofactors on Prediction o f Tumor
Uptake o f Gold Nanoshells.
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The large variation o f observed peak NP blood plasma concentration in the
Observation o f Cofactors on Prediction o f Tumor Uptake o f Gold Nanoshells CHAPTER
7), development o f the control feedback system (Section 3.2), and the study o f
Reticuloendothelial System Blockade and Redosing o f Gold Nanorods in a Murine
Model (CHAPTER 8) demonstrated a need for more uniform delivery o f NPs. This need
for uniform delivery spurred the need for improved injection protocols (Section 10.1) and
to make uniform delivery by observed blood plasma concentration enabled by the
NanoTracker (CHAPTER 9: Injection Normalization). These studies combined have led
to the development and improvement o f pre-clinical protocols for the utilization o f real
time blood plasma concentrations to improve the development o f individual and
population pharmacokinetic models o f gold nanoshells and nanorods in a murine model.

CHAPTER 2
LITERATURE REVIEW

2.1

Gold Nanoshells and Nanorods

The gold nanoparticies (nanoshells and nanorods) discussed in this dissertation
are provided by Nanospectra Biosciences, Inc. (NBI). Their nanoshells are currently in
multiple pre-clinical and clinical trials under an investigational device exemption (these
nanoparticies do not chemically interact with the body and are therefore classified as
devices, not drugs). The nanoshells are approximately 150 nm in diameter with a mPEG
coating, stored in an iso-osmotic solution o f 10% trehalose, and produced in the manner
described by Oldenberg and colleagues. [39], [40] Biodistribution o f these gold
nanoshells has been conducted, and will not be evaluated in the experimental section o f
this dissertation. James and colleagues demonstrated that at 1 day the gold was primarily
found in the organs o f the RES (Liver- 311 PPM, Spleen- 1890 PPM). [40]
The gold nanorods provided by NBI are approximately 15 x 45 nm, PEGylated,
and suspended in an iso-osmotic solution o f 10% trehalose. The nanorods are synthesized
using a modified version o f the method developed by Jana and colleagues [41] described
by Goodrich and colleagues . [37] Biodistribution o f these gold nanorods has been
conducted, and will not be evaluated in the experimental section o f this dissertation.
Goodrich and colleagues demonstrated the primary accumulation o f gold after one day
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was in the organs o f the RES (liver approximately 77% o f injected dose and spleen
approximately 6% o f injected dose). [37] Tucker-Schwartz and colleagues used
photothermal optical coherence tomography and PEGylated gold nanorods o f similar size
(synthesis roots that trace back to Jana and colleagues [41] through Murphy and
colleagues [42]) to monitor the accumulation and dissipation in mammary tumors, and
found the maximum accumulation to be at 16 hours. [43]

2.2

Clearance o f Gold Nanoshells and Nanorods

Nanoparticies are subject to rapid opsonization by complement and other proteins.
This opsonization is followed by removal from the blood by hepatocytes (particularly
particles <100nm) and macrophages o f the reticuloendothelial system (RES) within
seconds o f injection (creating short half-lives incompatible with passive targeting). [44],
[45] The Kupffer cells (tissue macrophages o f the liver) are unable to directly detect
foreign bodies in the blood, so this process requires the opsonization o f the nanoparticies
while they are circulating. Opsonins found on liposomes (a nanoparticle o f similar size
and shape to gold nanoshells) fall in two categories: immune opsonins and non-immune
opsonins. Immune opsonins include immunoglobulins, complement-related proteins (Creactive protein, serum amyloid P, or mannose-binding protein) and components o f the
complement system (such as C3, C4 and C5); non-immune opsonins include serum
proteins (such as albumin, a2-macroglobulin, apolipoproteins, laminin, fibronectin, etc.).
[44], [45]
The interactions o f complement and liposomes have been investigated but never
fully understood. Some o f the approaches taken to investigate these interactions include
measurements in plasma complement levels (through systems like ELISA and
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radioimmune assays) or changes in liposome structure (by release o f a drug or molecule
from the liposome); the latter demonstrates fewer parallels to gold nanoshells. Multiple
studies have demonstrated the activation o f complement through the classical pathway,
through both antibody-dependent and antibody-independent methods. Some studies have
demonstrated a difference in activating the classical or alternative pathway dependent on
cholesterol content o f the liposome. Scieszka and colleagues have demonstrated
opsonization dependent on heat-labile serum components, and that C3bi was responsible
for opsonization and uptake was enhanced by C5a. C3bi protein was proven responsible
through experiments using serum-lacking C3. The activation o f the complement system
through intravenous injection o f liposomes has also demonstrated sever anaphylactic
reactions. These reactions can be mediated through improving administration techniques
(such as adjuvant therapies or injection rate). [45]
Once a particle has been opsonized one o f three methods are commonly used to
make the phagocytic cells recognize the particle. The first method involves
conformational changes o f attached opsonin proteins from an inactive to an active protein
that is recognized by the phagocytic cells. The second method involve the attachment o f a
phagocyte to the particle by non-specific adherence to blood serum proteins. The third
method involves the activation o f phagocytes attracted to the activated complement
proteins attached to the particle. [44]
2.2.1

PEGvlated Nanoparticies
Charged and hydrophobic particles are more rapidly and efficiently removed by

the reticuloendothelial system, compared to electrically neutral particles. This high
removal rate created a need to make the particles electrically neutral or hide the particles
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by adding a surface coating. [27] Masking nanoparticies from the RES is necessary to
increase the circulation time to a period long enough for passive accumulation. This need
created a group o f “stealth” nanoparticies. The most common surface coating for stealth
nanoparticies is polyethylene glycol (PEG). A form o f PEG (DSPE-PEG) has been used
to demonstrate a concentration dependent suppression o f opsonizing proteins, and cholPEG or PE-PEG have been used to demonstrate a concentration dependent ability to
inhibit binding o f C lq with the ability to almost eliminate the binding at high enough
concentrations. [45] PEG uses steric hindrance to prevent the adsorption o f opsonins and
delaying the uptake by phagocytic cells. PEGylation o f nanoparticies is a common
method o f evasion o f the immune system and used in liposomes, polymeric nanoparticies,
gold nanoshells, and gold nanorods. PEG has several problems including liposomes
demonstrating a lower tumor accumulation compared to non-PEGylated liposomes, and
PEG is responsible for the accelerated blood clearance found upon repeated injections o f
PEGylated nanoparticies. Given the known problems with PEG, other surface coatings
(Polyoxazolines, Poly(amino acids), HPMA, Polyetaines, Polyyglycerols, or
Polysaccharides) should be considered. [27]
2.2.2

Accelerated Blood Clearance (ABC)

Upon repeated injections o f PEG liposome, a significantly shorter circulation half-life
was noted; if the repeated injections were given after a long enough delay the
pharmacokinetics returned to a similar to normal state. This phenomenon could be
transferred to other mice through transfusion o f serum, suggesting a soluble serum factor
was the cause. [46], [47] Some studies point to PEG as the source o f the ABC
phenomenon, however a change in PEG (density or length) can prevent ABC. [45] The

17

importance o f this phenomenon depends on the use o f the particular nanoparticle. If the
therapy is a one shot therapy, i.e. if the therapy can only be used once, it is not important
what the immune response would be to repeated injections. In the case similar to the
repeated doses o f DOXIL administration should be spaced appropriately to improve the
therapeutic index. [47]
2,2,3

Anti-PEG Immunoglobulin
Studies have suggested, through experimentation using “empty” PEGylated

liposomes, that a peg specific IgM (known to exist since 1983) contribute to the ABC
phenomenon. [48], [49] Ichihara and colleagues suggest that the mechanism responsible
for ABC could be anti-PEG IgM released after the initial dose o f PEGylated particles
binds to a subsequent injected dose o f particles. When the IgM attaches to the second
dose o f particles, the complement system is activated and the opsonization o f particles
that have activated C3 fragments. The attachments o f complement and IgM create a rapid
clearance o f the particles through the Kupffer cells o f the liver. [50]
Experiments have found PEG acts as a type two T cell-independent antigen and
primes the B cells in the marginal zone o f the spleen. This result was found through
elimination o f marginal zone B cells through the use o f cyclophosphamide. The T cellindependence was discovered through the use o f nude mice. Marginal zone lymphocytes
were eliminated through the use o f cyclophosphamide eight days prior to the injection o f
liposomes and serum was collected five days after the injection o f liposomes. ELISA
procedures were used to investigate presence o f IgM and IgG, which demonstrated a low
level o f anti-PEG IgM and IgG (implying the importance o f the marginal zone B cells in
production o f anti-PEG immunoglobulins). A separate study showed anti-PEG IgG at

three to five days and anti-PEG IgM three to ten days after the injection o f liposomes,
with a peak concentration around five days. Both IgM and IgG levels returned to normal
by fourteen days after the initial injection o f liposomes. The investigation o f
immunoglobulin response in the absence o f T cells was conducted using nude BALB/c
mice, and demonstrated anti-PEG IgM ten days after the initial injection o f liposomes.
Implying a T cell-independent mechanism for the production o f anti-PEG IgM. [48]
Through experimentation, Ishida and colleagues were able to establish a T cellindependent anti-PEG IgM response. This finding was discovered when anti-PEG IgM
was found in nude mice and not in SCID mice, suggesting the important mechanisms for
creation o f anti-PEG IgM were in the B-cells and not in the T-cells. Additional injections
o f liposomes did not cause isotype switching from IgM to IgG. These findings support
PEG acting as a type two T cell-independent antigen, and contribute to the current
understanding that B cells o f the spleen are the critical component in the ABC
phenomenon. The T-cell independent antigens (PEGylated particles in this case) did not
induce memory B-cells that produce IgG, explaining the loss o f the ABC phenomenon
given enough elapsed time from initial injection to subsequent injection. Testing for T
cell-independence involved testing using three groups o f mice: normal, nude, and SCID
mice. The levels o f serum immunoglobulin was similar in normal and nude mice, but for
all practical purposes absent in SCID mice, suggesting the T cell-independence.
Experiments conducted to suggest the importance o f the spleen involved the removal o f
the spleen from rats and subsequent injections o f liposomes; results showed
immunoglobulin production was reduced in rats with no spleen. Liposomes were
repeatedly injected at seven day intervals to demonstrate the T cell-independence o f PEG
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as an antigen. This study showed the first injection to result in the maximum anti-PEG
IgM production, limited isotype switching, and no generation o f B cell memory;
implying, T-cell independence. Serum samples for all the experiments were collected five
days after injection o f PEGylated liposomes and separated by centrifugation using serum
separating agents. [50]
Studies have been conducted to elucidate if ABC is caused by an increase in
phagocytic activity o f liver macrophages or if an increase in efficiency o f opsonization is
to blame. Rat livers were perfused with PEGylated liposomes designed to cause optimal
ABC. With the absence o f serum in the solution, no improved liver uptake was noted.
This finding suggests the liver uptake is not changed but the opsonization is. In addition,
procedures were followed to heat treat the serum; the results demonstrated a lower
serum-dependent liver uptake. These findings demonstrate the first dose o f PEGylated
liposomes do not increase the activity o f the Kupffer cells, and complement activation is
responsible and essential for ABC. [51 ]

2.3

NanoT racker

The NanoTracker is a non-invasive device developed to give near real-time
optical monitoring o f intravascular nanorods and nanoshells. This device works on the
same basic technology as a pulse oximeter, pulse photometry. Michalak and colleagues
says “We develop a pulse photometer capable o f accurately measuring the
photoplethysmogram in mice and determining the ratio o f pulsatile changes in optical
extinction between 805 and 940 nm, commonly referred to as R. these wavelengths are
selected to correspond to the extinction properties o f gold nanoshells”. [23] Michalak and
colleagues later describes the instrumentation involved, “Our device consists o f a probe
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compatible with mouse anatomy, analog circuitry, a data acquisition card, and LabVlEW
software”. [23] The probe includes an LED that emits at four unique wavelengths (660,
735, 805, and 940). This LED is purchased through Marubeni out o f Santa Clara,
California. Only the 805 and 940 nm wavelengths are used in the probe. A photodiode
(Hamamatsu Hamamatsu City, Japan) is used on the other side o f the subject to record
the changes in emitted light through the subject. The additional analog circuitry consists
o f filtering and timing systems, among other things.
The NanoTracker, a multispectral pulse photometer, is commonly used for mice
under light anesthesia or no anesthesia to detect the intravascular concentration o f
nanorods. The NanoTracker helps by providing the levels o f nanoshells or nanorods in
the vasculature, displayed as optical density. The NanoTracker does this by observing
pulsatile changes in optical extinction between 805 and 940 nm, and calculating a ratio
between the wavelengths known as R shown in Eq. 2-1, where VAc is the alternating
current voltage, VDC is the direct current voltage, Aj is wavelength 1, and A2 is
wavelength 2. [23]
Eq. 2-1

The NanoTracker then simultaneously solves Eq. 2-2 and Eq. 2-3 to solve for the
optical density o f the nanorods (ODNR) and oxygen saturation (5), using the R values,
effective attention coefficients o f oxygenated whole blood (Mh&o2) at wavelength (A), and
effective attention coefficients o f deoxygenated whole blood (/iHbo2) at wavelength (A).
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The use o f the NanoTracker allows us to obtain as many data points on the blood
plasma concentration curve as we would like, rather than being restricted by the amount
o f blood we can safely draw from the mouse for ex vivo optical density measurements.
This ability to obtain as many data points as desired is advantageous so we build a more
reliable blood plasma concentration curve. Another main advantage o f the NanoTracker
is the potential for use in near real-time applications o f pharmacokinetic models and
feedback controls during nanoparticle infusion.

2.4

Pharmacokinetics

“In Brief, pharmacokinetics is concerned with quantitatively accounting for the
whereabouts o f a drug after it has been introduced into the body. The analysis is carried
out through the entire time course for the drug in the body”. [52] The importance o f
pharmacokinetics is not always apparent; however, until the full biodistribution o f
nanorods is fully understood we will not be able to even speculate at what toxicity problems
could be faced. Even basic pharmacokinetic modeling is not a trivial task. This section
discusses two basic models, the one compartment and population pharmacokinetic models.
More advanced model such as a physiologically based models would be beneficial for a
better understanding o f the biodistribution. Physiologically based pharmacokinetic models
typically include significantly more compartments to account for more biological systems.
De Jong and colleagues conducted biodistribution studies, and demonstrated a presence o f
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gold nanoparticies (of multiple sizes) in the blood, liver, spleen, lung, brain, heart, and
kidney at 24 hours. [53]
2.4.1

One Compartment Model
A one compartment non-physiologically based model, shown in Figure 2-1, is

currently being used due to the availability o f data. The one compartment model for the
experimental data would represent the blood volume o f the mouse. Concentration o f
nanoparticies in the blood volume o f the mouse is available in the form o f experimental
data. The blood volume in a twenty-gram mouse is approximately 1.44 mL or 72 ml/kg.
The model uses Eq. 2-4 to give a concentration as a function o f time.

N

Nanoparticle Injection

Compartment One
Volume = V

Clearance ( K j

Concentration = C

Figure 2-1: Box Diagram demonstrating one compartment model.

C = C0e~ ket

Eq. 2-4

Where C is the concentration, C0 is the initial concentration, k e is the elimination
rate constant, and t is time. The initial concentration is calculated using Eq. 2-5.
Cn = ——
0 VOD

Eq. 2-5
H

Where D is the initial dose and VOD the volume o f distribution. Using this basic
model the half-life (tiy2) is calculated using Eq. 2-6.
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ln(2)

0.693

ke

ke

Eq. 2-6

This model demonstrates the removal o f the nanoparticies from the blood as a
function o f time. This model does not account for differences in the accumulation or release
o f nanoparticies from tissues, but only the overall removal o f the nanoparticies from the
blood.
Other models, such as two compartment physiological models, would provide a
better model o f the movement o f nanoparticies. These models would depend on the
availability o f real-time data reflecting accumulation in target tissues.
2.4.2

Population Pharmacokinetics
Population pharmacokinetics (popPK) investigate the variability between subjects

given the same treatment, also referred to as inter-subject variability. The focus o f popPK
involves studying and attempting to account for the inter-subject variability in terms o f
subject specific variables, such as age, sex, or weight. Studies often do not collect enough
data for the pharmacokinetic parameters o f an individual to be calculated. This lack o f
available data has skewed the meaning o f popPK to focus on analysis involving scarce
data. The developed popPK analysis techniques are applicable to studies with ample data,
but become a more valuable source o f analysis in studies with scarce data. The nature o f
sparse data does not allow for traditional analysis techniques. The need for novel analysis
techniques created several approaches such as nonlinear mixed effects modeling (Beal &
Sheiner 1982), non-parametric maximum likelihood (Mallet 1986), Bayesian (RacinePoon & Smith 1990). Nonlinear mixed effects modeling is the most popular method, due
in part to the software package NONMEM. [54]
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The title popPK conspicuously points toward the primary focus o f the analysis
techniques, populations not individuals. [54] This focus is a counterintuitive connection
with nanomedicine, where the focus is individualized medicine. However, the ability o f
popPK modeling to reveal sub-group specific effects (observed through covariates) can
help the clinician choose have more realistic expectations o f treatments should start to
obtain the desired outcome.

2.5

Elemental Analysis

Experimental studies in nanomedicine employ different types o f metal
nanoparticies. For example, gold nanoparticies are being used in animal and human trials
for assessing the feasibility o f photothermal ablation o f inoperable solid tumors. [21],
[35], [55] A potential way to enhance efficacy in such cancer therapies is to increase
feedback through additional clinical signs during the accumulation and treatment phases.
Nanoparticle systems could be coupled with individualized pharmacokinetics and
elemental analysis o f ex vivo tissue to confirm uptake and retention into the tumor.
Concurrently, innovative medical devices are being developed to provide nearinstantaneous pharmacokinetic feedback, [23], [36] suggesting the need for an elemental
analysis technique that provides similarly rapid quantitative feedback o f biodistribution.
These analyses could assess when, and to what degree, the particles were accumulating in
the tumor, or if they were being eliminated by the RES. The use o f rapid elemental
analysis coupled with real-time pharmacokinetic [23], [36] measurements could help
predict the most appropriate time for animal or human ablation (e.g. photothermal) o f the
tumor. For animal studies, a faster technique can have a major impact for companies
involved in nanomaterial quality control and product development. For human trials, the
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ability to measure, or predict, the accumulation o f the nanoparticies in the target tissues
could improve treatment outcomes for some o f the approximately 52,000 anticipated
deaths due to cancers targeted by this therapy each year, in the United States. [ 1]
Biodistribution o f gold nanorods is normally analyzed through inductively
coupled plasma mass spectrometry (ICP-MS) or instrumental neutron activation analysis
(1NAA). [30], [37], [40] ICP-MS requires elaborate and time-consuming sample
preparation (up to 104 hours). [56] INAA does not require a long sample digestion and
preparation, but requires longer analysis. [40] Although both o f these techniques are
accurate, they take from days to weeks to get results, longer than a clinical treatment time
o f one day. If the data were available within the clinical treatment time, we hypothesize
that some accuracy could be sacrificed compared to these standard methods.
Energy Dispersive X-Ray Fluorescence (EDXRF) is a technique used for bulk
and ppm elemental analysis that is rapid, robust and requires little sample preparation
time. [57] EDXRF has been previously used for quantitative in vivo and ex vivo analysis
o f gold in tissues like kidney and liver. [58], [59] Previous work with biological samples
demonstrates the need for thin samples, so that matrix effects can be neglected. [60]
Common EDXRF protocols require a long process o f drying, crushing, and pressing
samples into pellets. [60], [61] Based on guidance from the literature towards optimizing
a rapid sample preparation, the key aspects o f this protocol include: sample thickness,
geometry, and homogeneity. [60]
CHAPTER 5 outlines the procedure developed for a benchtop EDXRF elemental
gold analysis o f gold nanorods (~ 15 x 45 nm), an optically absorptive cylindrical nano
object used in nanomedicine. [37], [62] The protocol presented in CHAPTER 5 includes
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tissue digestion/homogenization in potassium hydroxide followed by desiccation in the
sample cup before EDXRF analysis. Using subcutaneous mouse tumors, the elemental
analysis was completed in less than 12 hours from the time o f tissue collection.

CHAPTER 3
MATHEMATICAL MODELING

The results o f CHAPTER 6 demonstrated poorer than expected correlations
between tumor uptake and standard pharmacokinetic metrics. This less than optimum
correlation generated a desire to observe additional variables. To find these variables we
turned to collaborative modeling efforts, and then continued with experimental
verification in CHAPTER 7.
Many people have used mathematical modeling o f tumor and tumor vasculature
toward different goals. Jain and colleagues used a model, established by their lab in 1988,
to study the changes on interstitial fluid pressure based on changes to “normalize” the
vasculature. [63] Chapman and colleagues used their modeling efforts to examine the
fluid flow through the leaky vasculature o f the tumor. [64] Frieboes and colleagues used
a mathematical model to understand some o f the variables that may help to explain tumor
growth and invasion. [65] Howard and colleagues demonstrated the use o f the unit
density sphere model as a practical alternative for clinical use compared to the
computationally demanding but more accurate Monte Carlo algorithms. [66] Soltani and
colleagues used a computational fluid dynamics simulation based on previous works to
study some o f the changes in pressure and introduced new parameters in this model. [11]
Goh and colleagues worked to develop a two-dimensional simulation platform to
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demonstrate the transport o f Doxorubicin to hepatomas, an elaboration o f previous work.
[67]
Goh and colleagues worked to create a two-dimensional simulation from a one
dimensional simulation. The goal was to be able to explore the special and temporal
variations o f doxorubicin concentrations and the penetration into the tumor and healthy
tissue. Other areas this model was designed to study are lymphatic drainage, and
intracellular kinetics. They were able to show that changing the injection volume does no
result in significant changes in drug concentration in the tumor or healthy tissue. They
also found that diffusion is the main transport mechanism o f free doxorubicin. Goh says
that some ways to improve the model would be to test the assumption o f spatially
independent physiological parameters, for fast growing tumors the boundaries between
zones should be examined, and the use o f a heterogeneous distribution o f drug molecules
in the blood. [67]
Soltani and colleagues used previous models and assumed a spherical tumor.
Some o f their assumptions included drug particles flow with the interstitial fluid. This
study demonstrated an increase in necrotic radius decreases the maximum pressure inside
the tumor, also they demonstrated that if a tumor is completely necrotic the interstitial
fluid pressure is zero. They also found that the transport o f a drug into a smaller tumor,
defined as being below critical tumor radius, is easier than larger tumors. They also
demonstrated that there is a critical necrotic radius. Above the critical necrotic radius the
effective pressure is such that it is easier for drugs to reach the center o f the tumor. [11]
The work o f Howard and colleagues is focused on the treatment o f non-Hodgkin’s
Lymphoma. The model used is trying to demonstrate usefulness for patient specific
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dosimetry-based treatments. This planning requires an accurate assessment o f the
radiation absorbed by the healthy tissue. The majority o f these calculations are
predetermined by Monte Carlo algorithms and use a “reference man” for the anatomy. An
optimal situation would allow for 3D imaging o f the patient to be used in the Monte
Carlo algorithm rather than the “reference man.” They have created a unit density sphere
model incorporated in previously established models. This ideal situation would create an
extremely calculation heavy treatment system, therefore becoming less clinically
available. The conclusions o f this study show the sphere model is more applicable due to
the lower computational needs, but can be less accurate and therefore not useful in all
applications. [66]
The work o f Chapman and colleagues focuses on modeling the fluid flow through
the capillary o f a tumor. Their model describes fluid flow through solid tumors, and uses
a number o f different capillary lengths. Some o f the assumptions they used in their model
include using blood as a Newtonian fluid, where the model could be improved by using
blood as a shear-thinning fluid. Other assumptions that they used and could be changed to
improve the model include the viscosity o f blood. They claim that as the plasma leaks out
of the capillary it would alter the hematocrit and therefore change the viscosity; this
change would create a need for additional feedback in their model. They also suggest that
their model could be improved if further work included a pressure-dependent capillary
radius. [64]
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3.1

Monte Carlo

Mathematical modeling o f tumor and tumor vasculature have been proposed and
implemented to address different goals. With their model established in 1988 [68], Jain
and colleagues studied the effect o f antiangiogenic agents on the tumor IFP. [63] The IFP
o f various tumors was calculated based on the transport properties o f the capillary wall
and interstitium and a decrease in the IFP o f the tumors after antiangiogenic treatment
was reported. The decrease in IFP occurs because the capillary walls are less permeable
than before the treatment. From the point o f view o f the nanoparticle-based treatment,
this imposes a trade-off between a more efficient delivery due to a larger pressure
gradient from the capillary to the tumor, but through a less permeable wall. The fluid
flow through the leaky vasculature o f the tumor was also studied using modeling. [64] In
that model, the flow along the capillaries, across the capillary walls, and through the
interstitium were described by Poiseuille’s [25], Starling’s [69], and Darcy’s laws [70],
respectively. However, in their study the authors treated blood as a Newtonian fluid.
Frieboes and colleagues used a mathematical model to understand some o f the
variables that may help to explain tumor growth and invasion. [65] Soltani and Chen [11]
developed a numerical model to study the fluid flow in the tumor interstitium where the
tumor tissue was assumed to be spherical and the fluid flow was governed by
conservation o f mass and momentum. They studied the fluid velocity and interstitial fluid
pressure as a function o f the tumor size. Chang and colleagues, developed a network
model to study the delivery o f colloidal drugs [9] where the tumor interstitium was
represented by a 2-D square network while the movement o f colloidal particles in the
interstitium was simulated by the Brownian dynamic simulation method. Drug delivery

for different drug concentrations and different interstitial pressures was studied in that
work.
Models to predict nanoparticle transport and uptake in tumor tissue have also been
discussed in the literature. Goodman and colleagues [71] developed a mathematical
model o f nanoparticle transport in a non-uniform porous spheroid representing a tumor.
Nanoparticle diffusion into spheroids and particle binding and dissociation at the cell
surface was modeled. The effect o f the number o f binding sites and pore distributions in
the spheroid on the nanoparticle transport and accumulation is studied. Nanoparticle
accumulation was predicted to be non-uniform but correlated with the porosity o f each
region in the tumor model. Styiianopoulus and colleagues [72] developed a methodology
to calculate the diffusion coefficients o f macromolecules and nanoparticles in
collagenous tissues resembling the interstitium. The tissues were modeled as threedimensional, stochastic, fiber networks with varying degrees o f alignment. The study
predicted that the structure and orientation o f collagen fibers in the extracellular space
affects the isotropy o f nanoparticle distribution, with more aligned fibers resulting in a
more anisotropic distribution. Frieboes and colleagues [73] modeled the accumulation o f
nanoparticle in tumor vasculature at different tumor stages. Their model simulates the
growth o f cancer tissue and predicts the accumulation o f nanoparticle in its vasculature
for different sized nanoparticle. They predict that increasing the affinity o f nanoparticles
for vessels results in their accumulation at the tumor inlet leading to a poor delivery to the
tumor core and outlet vessels; in contrast, reducing the vascular affinity produces a more
uniform nanoparticle distribution but also reduces the overall nanoparticle delivery.
Mishra and colleagues [74] on the other hand, study the tumor response to the
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nanoparticles delivered. Their model describes the nanoparticle concentration in the
tumor cell and the tumor cell movement. Their model predicted an exponential reduction
o f tumor size as a long-term response to the treatment for both 10 nm and 100 nm
nanoparticle. The effect o f nanoparticle’s shape and size has also been addressed, [75]
reports experimental evidence that size, shape, and surface properties all play a role in the
nanoparticle accumulation in the vasculature with 1000 nm x 400 nm plateloids being
predicted to provide a rapid and larger than ever reported before accumulation of
nanoparticle in tumor. A mathematical model is then used to predict the probability o f
nanoparticle adhesion to the blood vessel that shows maximum adhesion for nanoparticle
o f 1000 nm in size in agreement with the experiment. The model also predicts that lateral
drifting diminishes with size and it is smaller for spherical than for anisometric
nanoparticle, as lateral drifting allows periodic interactions with the lateral wall, show
smaller and more symmetric nanoparticles lower accumulation
The objective o f the computational model developed by the Derosa group is to
track nanoparticles in the blood stream and into the tumor through the capillary wall and
to predict nanoparticle delivery as a function o f controllable parameters that can be
adjusted to optimize the delivery. [28] Nanoparticle transport is obtained from the
velocity o f the blood flow over imposed with Brownian motion. The blood vessel in the
model is designed as a cylindrical tube with a single pore o f a size in the range o f the
tumor capillary wall pores. This model is able to predict the dependence o f the
nanoparticle’s delivery to the tumor tissue on blood pressure, interstitial pressure, size,
and concentration o f nanoparticles in the blood stream, and pore size. The model
incorporates the parameters that characterize tumors and distinguish them from normal

33

tissue (such as high IFP and larger pore size), and simulates nanoparticle flow through
the capillary wall as an extravasation event. Since drug and medical device development
relies on design specifications that meet end-user needs and integrate a process for
evaluation o f performance metrics, the model presented here seeks to serve as a tool to
predict the effect o f relevant parameters on the uptake o f medical nanoparticles, and thus
provide parameters that can be used for future designs.
A model to simulate nanoparticle delivery to leaky solid tumors is presented. The
study indicates that nanoparticle delivery increases with pore size. Hyperthermia [76], or
any other mechanism which increases the pore size in the tumor blood vessel wall, is
predicted to increased drug delivery. Smaller particle size leads to the same effect of
increasing delivery; however, deliver is found to be more sensitive to pore size than to
particle size. The reason is that in addition to increasing the pore/nanoparticle size ratio,
the velocity o f the fluid entering the pore increases with pore size, thus increasing the
drag force. This effect has been observed in the velocity profile near the pore. Increased
concentration o f the nanoparticles in the blood leads to a linear increase in the number o f
nanoparticles delivered, but the relative efficiency with which they are delivered is
virtually independent o f the concentration.
The model proposed by the Derosa group [28] and described below shows
agreement with the experimental information available and produces results that satisfy
the author’s logic in those cases where no experimental evidence is available. Application
to other cases leads to provocative predictions, such as the different dependence o f
delivery on nanoparticle size for different tumor IFPs. It was found that the sensitivity o f
nanoparticle delivery to particle size decreases when IFP decreases (increasing the
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pressure gradient from the capillary to the tumor). For the case studied here, for instance,
there is a clear decrease in nanoparticle delivery with size until an IFP o f about 18
mmHg; for lower IFP, the delivery is virtually insensitive to particle size. The same effect
is observed as blood pressure increases, due to the same reason that the pressure gradient
across the pore increases. All o f these predictions would benefit from experimental
verification and the authors expect this paper can motivate those experiments.
Although the collective effect o f delivery through several pores is an aspect o f
this process that has not been considered in the work, this can be treated as the
cumulative delivery through one pore at a time by appropriately adjusting the
nanoparticle concentration. However, IFP changes as blood flows in the tumor will need
to be taken into account, where large doses are to be simulated, any large accumulation o f
particles may change the IFP, and thus studies o f the interstitium are called for.
Predictions o f total doses delivered to a tumor can be obtained by taking into
consideration the decrease in nanoparticle concentration as they flow down the blood
capillary.
Finally, it is important to mention that nanoparticle aggregation, if the aggregate
are numerous enough and make it to the capillary, will certainly affect nanoparticle
delivery, as shown in this work. Although particle size is a factor in delivery and
aggregation will lead to much larger particles, nanoparticle aggregates formed within the
body are quickly removed from the blood circulation by the liver and spleen. [77], [78]
Aggregates would circulate for such a short period o f time that their presence in the
capillary bed could be neglected. Hence, nanoparticle aggregations are not considered in
the model.

35

The Monte carol model developed by the Derosa group was designed to simulate
a blood capillary with one pore. The nanoparticles used were spherical in shape and
similar to the gold nanoshells discussed in CHAPTER 4 and CHAPTER 7 (given the
correct size). The NPs were acted upon by two forces, the flow o f blood and Brownian
motion. The flow o f blood was modeled using a pressure-driven flow model o f a nonNewtonian fluid in a cylindrical tube with “sticky” walls, which provided a parabolic
velocity profile with the maximum velocity at the center o f the capillary. The Brownian
motion component was calculated using randomly assigned distances and angles for
movement. COMSOL was used to establish a zone where the pore had an effect on the
movement o f the particles. This zone was established by creating two simulations in
COMSOL (with and without a pore) and noting the zone where the pore has an effect on
the fluid flow. The progression o f a NP through the Monte Carlo modeled cylinder is
outlined in Figure 3-1. The O ’Neal group contributed to the work o f Podduturi and
colleagues by providing physiological relevance to the model parameters and
contributions o f early data for the Derosa group to evaluate the functionality o f the
model. [28]
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c y lin d e r , a n e w H ? i s d e liv e r e d t o t h e c y l i n a e r t o k e e p
a c o n s t a n t c o n c e n t r a t io n

Figure 3-1: Progression o f a NP through the Monte Carlo model. Adapted from the
work o f Podduturi and colleagues. [28]

This work is unique in the portion o f the nanoparticle delivery system it is
modeling. The papers discussed and referenced in this section provided background
information on the state o f mathematical modeling o f this system at the time o f this work,
and provided guidance for parameter values to contribute to the development o f this
model. The collaborative work between the Derosa and O ’Neal groups, in conjunction
with the data presented in CHAPTER 6: Use o f Real-Time Pharmacokinetics to Predict
Tumor Uptake o f Gold Nanorods, resulted in a peer-reviewed publication titled
“Simulation o f Transport and Extravasation o f Nanoparticles in Tumors Which Exhibit
Enhanced Permeability and Retention Effect”. [28]

3.2

Controls

Collaborative work investigated the use o f a controller with the objective o f
output tracking. Meaning the controller was attempting to make the blood plasma
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concentration o f nanoparticles remain within a desired (assumed) “therapeutic window”
for the longest time possible with a minimal effort (minimize number o f injected
particles). The control implementation chosen involved a linear quadratic regulator state
tracking design. This work used the blood plasma concentration curves from 0 to create a
“Master Mouse” for each group (A and B) to observe the behavior o f the nanorods. The
model then continues to use four different injection profiles: linear (constant injection
rate), positive quadratic (increasing injection with time progress), negative quadratic
(faster initial rate and slowing with time progress), and an exponential curve. All results
demonstrated similar total control efforts, but the positive quadratic had the minimal
effort. [79] This work with a controller will be significantly more interesting once a
therapeutic window has been established, and we are able to use these control systems to
target specific AUC values or maintenance in a therapeutic window for a specific time to
achieve a desired result. These controls will be able to minimize system effort and create
a constant AUC.
This work is in conjunction with the data presented in CHAPTER 6: Use o f RealTime Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods, and resulted in a
peer-reviewed conference proceedings titled “LQR Tracking o f a Delay Differential
Equation Model for the Study o f Nanoparticle Dosing Strategies for Cancer Therapy”.
[79]

CHAPTER 4
ANIMAL PROTOCOL REVIEW USING
GOLD NANOSHELLS

4.1

Specifications and Introduction

The purpose o f this set o f experiments is to follow and review the established
protocols. These experiments will inform protocol updates implemented in CHAPTER 6:
Use o f Real-Time Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods. The
primary focus these protocol reviews is a retrospective analysis o f the pulse photometer
data collection and processing, and the need to continue blood draw protocols
(APPENDIX A: Mouse Blood Draw Protocol). The result o f these experiments include
recommendations for protocol updates to be used in CHAPTER 6: Use o f Real-Time
Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods. These experiments are
broken down into two separate trials: Hyperthermia and Long vs. Short.
4.1.1

Hyperthermia
As part o f a continued effort to decrease injected volume, several parameters are

being studied to look for changes in circulation times. One o f these parameters leads us to
study how hyperthermia will affect the circulation time o f nanoparticles. Studies have
shown that hyperthermic conditions up to 42°C show increased extravasation. [29] The
previous study looked at hyperthermia over a specific period, where the study presented
here keeps the subject in elevated ambient environment conditions through the entire
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accumulation phase. Some believe the effect o f temperature difference on the circulation
time is mainly based on peripheral vasodilatation in hot environments. Regardless of
mechanism, previous studies have observed pore cutoff size increased to greater than 400
nm at 42°C. This increase in pore size allowed significant accumulation o f particles up to
400 nm, when compared to normothermic conditions. [76] With more blood being sent
through peripheral circulation to dissipate heat more nanorods may be able to avoid the
macrophages o f the RES mainly located in the liver and spleen. However, some studies
have suggested that fever range hyperthermia could increase immune efficiency. [80] If
this effect is observed with the RES, the nanorods could be cleared from the blood more
rapidly. This study was designed to look for observable differences in circulation time
between the hyperthermic subjects and control subjects.
4.1.2

Long vs. Short
A third study will look into the difference in tumor accumulation and circulation

time depending on the time over which the injection o f a standard amount o f
nanoparticles is given. For example, a standard amount o f nanoparticles will be given
over a period o f less than thirty seconds for one group and another experimental group
would receive their injections over a period o f ten to fifteen minutes. This study will be
conducted without tumors then repeated using tumors. The iterations o f the experiment
will provide data on circulation time and tumor accumulation.

4.2

Materials and Methods

All o f the studies involve animal work conducted under protocol approved by the
Louisiana Tech University Institutional Animal Care and Use Committee (IACUC). The
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animals were handled in accordance with the ‘Guide for the Care and Use o f Laboratory
Animals’.
4.2.1

Hyperthermia
Eight naive BALB/c female mice with intact thermoregulatory systems were used

to study the effects o f hyperthermia on circulation half-life o f experimental gold
nanoshells (NB1, Houston, TX).
The experimental group o f mice was placed in a forty-two degree Celsius
environment for a minimum o f forty-five minutes prior to injection. The mice were
anesthetized using isoflurane anesthesia (given at 1 liter per minute at 4% for induction
and 2% for maintenance), and the nanoshells (a standard dose o f 4.5 pL/g) were injected
over 10 seconds via tail vein. Once any procedure on the experimental mice was
completed, the mouse was put back in the forty-two degree Celsius environment.
The control mice were placed in a thirty-six degree Celsius environment for a
minimum o f forty-five minutes prior to injection. The mice were anesthetized using
isoflurane anesthesia (given at 1 liter per minute at 4% for induction and 2% for
maintenance), and the nanoshells (a standard dose o f 4.5 pL/g) were injected over 10
seconds via tail vein. After injection, the mice were kept at room temperature (20-26°C)
throughout the experiment.
4.2.2

Long vs. Short
Four naive BALB/c female mice with intact thermoregulatory systems were used

to study the effects o f injection rate on circulation half-life o f experimental gold
nanoshells (NBI, Houston, TX).
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The experimental group o f mice was placed in a thirty-six degree Celsius
environment for a minimum o f forty-five minutes prior to injection. The mice were
anesthetized using isoflurane anesthesia (given at 1 liter per minute at 4% for induction
and 2% for maintenance), and the nanoshells (a standard dose o f 4.5 pL/g) were injected
over 1 minute via tail vein. Once any procedure on the experimental mice was completed,
the mouse was returned to housing during the accumulation phase.
The control group o f mice were placed in a thirty-six degree Celsius environment
for a minimum o f forty-five minutes prior to injection. The mice were anesthetized using
isoflurane anesthesia (given at 1 liter per minute at 4% for induction and 2% for
maintenance), and the nanoshells (a standard dose o f 4.5 pL/g) were injected over 10
minute via tail vein. Once any procedure was completed, the mouse was returned to
animal housing, for the duration o f the accumulation phase.
4.2.3

Intravenous Catheters and Cannulation
Intravenous cannulas were made using 2 French Polyurethane Catheter tubing

(Access Technologies, Skokie, IL Cat. No BC-2P). On one end, used as the needle for
vascular access, a 28-gauge needle was removed from an insulin syringe (Tyco/
Healthcare '/» mL 28G x Vi' insulin syringe REF # 1188528012, VWR Cat. # 84009-742)
and attached to the tubing. On the other end o f the tubing a 27 gauge needle (Becton
Dickinson 27G x Vi' REF 305109, VWR Cat. # BD305109) was added for slip tip or luer
lock access to the cannula. Injection solution was loaded in a lmL insulin syringe
(Becton Dickinson 1 mL syringe REF 329650, VWR Cat. # BD329654). Injection
volume and rate were ensured using a syringe pump (New Era Pump Systems, Inc.
Farmingdale, NY. Model # NE-1010).
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4.2.4

Temperature Control
Temperature regulation o f the mice prior to injection was achieved using a

shaking incubator, with the shaker o ff (Labnet International, Inc. Edison, NJ. Model #
21 IDS). During injection and while the mice were under anesthesia the temperature was
controlled using a heating pad (Physitemp Instruments, Inc. Clifton, NJ. Model # TCAT2LV) and a space heater for ambient air temperature (Sunbeam Products, Boca Raton,
FL. Model # S F H 1 11).
4.2.5

Gold Nanoshells
PEG modified gold nanoshells were obtained from NBI. The absorption spectra o f

the nanorods was obtained using a UV/Vis spectrophotometer (Beckman Coulter DU 800
Brea, CA.). A 1% dilution o f nanorods was made using 10% Triton X to obtain the
absorbance at 600, 805, and 940 nm. These values are required as input values o f the
NanoTracker to ensure proper calculations.
4.2.6

Blood Plasma Concentration Observations
Blood plasma concentration was observed (under isoflurane anesthesia) at

intervals o f approximately 20 minutes post injection, 90 minutes post injection, end o f the
first half life, 1.33 half-lives, 1.66 half-lives, and at the end o f the second half life. These
times were based on an assumed six-hour half-life, and altered if an extremely long or
short half-life was noted. If it was not possible to collect data at those exact times for any
reason the data point was taken early or late to get as close to the correct time as possible.
4.2,6.1

NanoTracker
Blood plasma concentration was collected using the NanoTracker; data points

were taken before and after the blood draw. The operator manually recorded the blood
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plasma concentration values, and attempts were made to ensure data was o f sound quality
(standard deviations less than 0.03, on the mean o f an averaged 5 seconds o f data).
4.2.6.2

Blood Draw Protocol
The blood plasma concentration was confirmed using an established ultraviolet-

visible spectroscopy (UV/Vis) protocol (APPENDIX A: Mouse Blood Draw Protocol).
The blood for the UV/Vis protocol was collected by snipping the end o f the tail and
collecting five micro-liters o f blood using a pipette coated in Ethylenediaminetetraacetic
acid (EDTA).
4,2,7

One-Compartment Pharmacokinetic Model
The data from each mouse was manually entered to a spreadsheet and plotted. The

data was assumed to fit a standard one-compartment pharmacokinetic model; an
exponential trend line was added and used to calculate relevant pharmacokinetic metrics.

4.3

Results

Table 4-1 displays the half-life for each mouse involved in the hyperthermia study
for data collected from both the NanoTracker (NT) and absorbance spectrometry
(UV/Vis). Both groups demonstrated similar half-lives; a t-test was used to demonstrate
strength o f the similarity between the two groups. The number o f mice in each group
suggests that a t-test is not fully applicable in this situation, but it is simply being used to
demonstrate the strength o f the similarity between these two groups. The third column
(the second UV/Vis) excludes the data for mouse 1. This piece o f data causes a 22% drop
in the average half-live value for hot mice. When this extreme outlier is removed the data
demonstrates no statistically significant difference between the experimental and control
groups. The data in the UV/Vis groups have a higher probability o f error due to the
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complicated protocol and the need for extreme accuracy in each step. This accuracy
would have been difficult for a newly trained group to obtain. This inexperience means
the NT data should be considered more accurate for this study. This data suggests that
there is no difference in the circulation patterns o f nanoparticles based on ambient
temperature during circulation. This finding suggests that any future study demonstrating
different pharmacokinetics during accumulation/circulation would be attributed to
differences in uptake and retention in tumors rather than differences in immune response.
Table 4-2 displays the half-life for each mouse involved in the long vs. short
study for data collected from both the NanoTracker (NT) and absorbance spectrometry
(UV/Vis). Both groups demonstrated similar half-lives; a t-test was used to demonstrate
strength o f the similarity between the two groups. The number o f mice in each group
suggests that a t-test is not fully applicable in this situation, but it is simply being used to
demonstrate the strength o f the similarity between these two groups. These data suggest
that there is no difference in the circulation patterns o f nanoparticles based on length of
injection. This finding suggests that any future study demonstrating different
pharmacokinetics during accumulation would be attributed to differences in uptake and
retention in tumors rather than differences in immune response.
4.3.1

Hyperthermia
The hyperthermia experiments demonstrated an average half-life o f 150 and 160

minutes for cold and hot mice, respectively (shown in Table 4-1).
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Table 4-1: Half-life (in minutes) for cold and hot mice calculated from NanoTracker
and Blood Draw (UC/Vis) protocols.

Cold

Hot

NT

UV/Vis

Mouse 1

170

115

Mouse 2

98

128

Mouse 3

180

135

Mouse 4

150

128

Mouse 1

81

9

Mouse 2

99

33

Mouse 3

201

115

Mouse 4

258

113

When the groups o f mice were compared, the p-values from a T-Test were 0.83
and 0.08 for NanoTracker, and UV/Vis, respectively. These p-values suggest we are
unable to reject the null hypothesis o f the means being equal, for a=0.05; there is not
sufficient evidence to prove these groups are dissimilar. These sample sizes do not reflect
a large enough population for parametric statistics to provide useful insights. Graphs o f
the blood plasma concentration (representing the concentration o f compartment 1 in a
one-compartment model) are shown for hot and cold mice (Figure 4-1 and Figure 4-2,
respectively).
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Figure 4-1: Blood Plasma Concentration vs. Time Hot Mouse 3. This chart is an
example o f the data charted for the one compartment exponential decay o f a mouse
kept in a hot environment with NanoTracker and blood draw data.
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Figure 4-2: Blood Plasma Concentration vs. Time Cold Mouse 1. This chart is an
example o f the data charted for the one compartment exponential decay o f a mouse
kept at room temperature with NanoTracker and blood draw data.

4.3.2

Long vs. Short
The long vs short experiments did not demonstrated a large change in half-life in

the long mice, but did in the short mice (shown in Table 4-2).

Table 4-2: Half-life (in minutes) for long and short mice calculated from NanoTracker
and Blood Draw (UV/Vis) protocols.

Long
Short

Mouse
Mouse
Mouse
Mouse

NT
1 113
2 106
1 166
2 84

UV/Vis
119
77
118
142
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When the groups o f mice were compared, the p-values from a T-Test were 0.74
and 0.32 for NanoTracker, and UV/Vis, respectively. These p-values suggest there is no
significant difference between the means o f the long and short mice, for ot=0.05. These
sample sizes do not reflect a large enough population for parametric statistics to provide
useful insights. Graphs o f the blood plasma concentration (representing the concentration
o f compartment 1 in a one compartment model) are shown for long and short mice
(Figure 4-3 and Figure 4-4, respectively).
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Figure 4-3: Blood Plasma Concentration vs. Time Long Mouse 1. This chart is an
example o f the data charted for the one compartment exponential decay o f a long
injection with NanoTracker and blood draw data.
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Figure 4-4: Blood Plasma Concentration vs. Time Short Mouse 1. This chart is an
example o f the data charted for the one compartment exponential decay o f a short
injection with NanoTracker and blood draw data.

4.4

Discussion and Review o f Specifications

The data itself does not represent a large enough population to draw significant
conclusions. A power analysis o f the group suggests a necessary sample size (in each
group) o f 58 and 10 for Hyperthermia and Long vs. Short, respectively (a=5% P=80%).
The large number o f mice required to demonstrate a significant result for the
hyperthermia experiment suggested continuing these protocols for a significant result
would require too many animals and was thus was unrealistic. The continuation o f these
protocols to a significant result would also not fulfill the primary goal o f this study, a
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retrospective review o f protocols. The small number o f completed mice was able to
provide necessary researcher experience to complete a primary stage retrospective
protocol review.
The primary goal o f these experiments was a retrospective protocol review. The
most obvious lesson learned is regarding collecting and saving data, given the need to
ensure all data meets standards. It is extremely difficult to observe the standard deviations
o f the two channels and record the piece o f data in the five seconds while the number
flashes across the screen. It is impossible to calculate the heart rate and ensure that all
three heart rates are within 20% o f the mean for each second, and the AC signal
amplitude is between three and 100 mV each second. In addition, it was determined the
data signal deteriorated with time. This problem resulted in two recommendations: ensure
the mouse is kept warm during the time o f data collection (to encourage adequate
peripheral blood flow), and discontinuing the practice o f collecting NanoTracker data
under anesthesia. The final major protocol change is related to the confirmation o f each
point using blood draw protocols. The use o f drawing blood from the animal comes into
question due to the sampling without replacement. This sampling will result in a large
change o f blood volume o f a mouse. This change in volume has caused other researchers
to not observe blood plasma concentration during the accumulation phase o f a tumored
experiment. With the primary goal o f future studies to involve the pharmacokinetic
modeling o f the accumulation phase, it was necessary to eliminate the blood draws.
A review o f specifications is presented in Table 4-3, and the data from this set o f
experiments was presented at the “Southern Biomedical Engineering Conference’*in
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Arlington, Texas on April 30, 2011. The abstract from this presentation was published in
the associated conference proceedings. [81]

Table 4-3: Summary o f observed protocol problems and solutions.
Observed Problem
Inability to meet heart rate and AC
magnitude data requirements, and
difficulty observing standard
deviation
Non-uniform creation o f graphs and
large amount o f anticipated data
from future saved files

Solution
Save data and create rapid review algorithm.

Create MATLAB code to rapidly process
“good” data and create uniform graphs.
•

Data quality deterioration.
•
Impractical for use o f blood draws
related to tumored experiments, in
addition they create a large human
“bandwidth” problem for processing.
Staining on tail post Au nanoshell
injection

Discontinue use o f anesthesia during
data collection
Use space heaters to keep mouse warm
Discontinue blood draw protocol.

Slow injection rate to reduce risk o f staining
on tail.

CHAPTER 5
DEVELOPMENT OF AN ENERGY DISPERSIVE
X-RAY FLUORESCENCE (EDXRF)
TECHNIQUE FOR ELEMENTAL
ANALYSIS OF GOLD
NANORODS

5.1

Introduction and Specifications

Throughout the work in the initial experiments o f CHAPTER 6: Use o f RealTim e Pharmacokinetics to Predict Tumor Uptake o f Gold Nanorods w e found a need for

tumor uptake data faster than the traditionally used 1NAA. The old elemental analysis
methods required batches o f tumors to be sent off for analysis taking 4 to 6 weeks. This
delay was found to be unreasonable for use in preclinical protocol and particle
development. In addition to the pre-clinical problems, the methods were impossible for
implementation in clinical settings where the data would be needed in under 12 hours for
use in clinical decisions. These needs led to these specifications:
•

Tissue analysis completed in less than 12 hours

•

Minimized skilled tasks to minimize potential error

Our lab group has chosen EDXRF as a system for elemental analysis o f tissue
samples for several reasons, the main reason being the machine is readily available. This
quick turn around on samples makes our research go much smoother with a greater level
o f confidence in our work. We are able to have the amount o f gold in a tumor within 36
52
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hours o f the initial injection o f nanorods into the mouse. This information is very
important in guiding the next animal experiments.
This device uses x-ray excitation o f a sample to characterize the elemental
composition. X-rays are used to excite electrons from ground state to create an electron
hole. This hole is filled by an electron in an outer shell. The energy difference from the
electron moving from higher to lower energy is released as an x-ray. The released x-rays
are then measured by an energy-dispersive spectrometer.
The specifications for the development o f this elemental analysis protocol are:
•

Complete sample analysis 12 hours after collection.

•

Minimal sample preparation.

5.2
5.2.1

Materials and Methods

Animal Experiments
All experiments were conducted using BALB/c female mice inoculated with

CT26.WT tumors on the subcutaneous flank. The accumulation experiment was
performed on animals with a target tumor size o f greater than 5 mm in length and width.
All animals were handled and cared for in accordance with the Louisiana Tech University
and Nanospectra Biosciences, Inc. (NBI, Houston, TX) Institutional Animal Care and
Use Committees.
5.2.2

Temperature Control
Prior to injection and for three and a half hours after injection the animal was kept

under specific temperature control (35-39°C), to facilitate intravenous cannulation and to
normalize the extravasation o f the gold nanorods. [37]
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5.2.3

Dose Groups
For this experiment, two dose groups were used. Both o f the groups were based

on the multiples o f standard dose administered by NBI. The first group received 4.5 pL/g
subject weight o f 100 optical density gold nanorods (Dose group A) and the second group
received 9 pL/g o f 100 optical density gold nanorods (Dose group B).
5.2.4

Anesthesia
For this experiment we used 2,2,2-Tribromoethanol (Sigma-Aldrich T48402)

mixed with 2-Methyl-2-Butanol (Alfa Aesar A18304), more commonly referred to as
Avertin, administered via intraperitoneal (IP) injection. The working solution o f Avertin
was administered at 30 pL o f solution per gram body weight. Booster injections (0.5x)
were delivered as necessary.
5.2.5

Injection
Nanorod injections were administered via intravenous cannulation o f the tail vein,

using a 28 GA needle. The injections were given at a rate o f 9-18 pL/minute depending
on dose volume and expected remaining time under anesthesia.
5.2.6

End o f Experiment and Organ Collection
At the end o f the experiment, defined as when the blood plasma concentration o f

circulating nanorods reached one optical density, [36] a 20 pL IP injection o f a Ketamine/
mix was administered as heavy anesthesia. A dissection was started from the base o f the
abdominal cavity to sacrifice the animal by exsanguination via cardiac puncture using a
22 GA needle/syringe prefilled with 100 pL o f heparin. After animal sacrifice, the
following tissues were collected for further study: heart, lungs, liver, kidneys, spleen, and
tumor.
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5.2.7

EDXRF Sample Prep
A wet weight o f the tissue was obtained at the time o f extraction. A 20% w/w

KOH solution was added to the tissue based on the sample weight (3 pL/mg). The tissue
and base solution were placed in a shaker or rocker until the tissue liquefied,
approximately four to six hours. Aliquots o f 35 pL (selected to cover our area o f
detection: 15 mm x 12mm, containing approximately 0.04 g o f tumor tissue) were placed
in EDXRF sample cups on a Prolene® thin film support (Chemplex Industries Inc., 4pm
thick, Cat. # 3017). The tissue solution was then dried in the sample cup for two hours in
a vacuum oven at 30° C under 15 in Hg vacuum to reduce the movement o f sample. The
samples were analyzed in an ARL Quant’X (Thermo Scientific) EDXRF spectrometer (450 KV x-ray generator, Be window, with 80°geometry between x-ray tube, sample, and
detector) using a thick Palladium filter (Mid-Zc range) for two minutes (50% dead time).
Three replicates were prepared from most tissue samples. Each sample cup was scanned
ten times which produced up to 30 spectra for each tumor. The spinner was turned on
during each scan to minimize error from the sample placement in the cup.

5.3

Results

The doped tumor samples were plotted and fit with a linear trend line (Eq. 5-1,
where PPM is the calculated sample concentration in parts per million and PI is peak
intensity in counts per second per milliamp) for use as a calibration curve (shown in
Figure 5-1).
PI = 0.0729 * PPM + 0.0174

Eq. 5-1
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This method has a detection limit (3c) o f 1.4 ppm and a sensitivity o f 0.07
cps/m A/PPM.

U4

y = 0.073x + 0.0127
R2 = 0.9838

0 Efr
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Gold Concentration (PPM)

80

Figure 5-1: EDXRF Calibration. This graph demonstrates the raw calibration points
(□), used calibration curve (dashed line), and a 95% confidence interval (solid line).

5.4

Discussion

The EDXRF protocol for gold in tissue was designed with the following aims:
quick and easy sample preparation, thin samples, and quantitative results. A 20% K.OH
solution was chosen, after experimentation, to minimize the time for liquefaction o f the
tissue. Thin sample geometry was implemented because thick samples were impractical
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given the amount o f tissue available, and to avoid intermediate sample thickness. An
aliquot o f 35 pL o f tissue was selected to create a thin sample area entirely in the
detection geometry o f the detector. Quantitative results were obtained using the same
tissue dilutions and same sample scan time; doped tissue samples for calibration were
able to provide a linear relationship between counts and tissue concentration.
The calibration curve was used to obtain the values o f concentrations (in ppm) for
tumor samples (dose group A: n=8, mean = 10.7 PPM, STDEV = ±5.8 PPM, and dose
group B: n=9, mean = 25.3, STDEV - ±6.9 PPM). An analysis o f the peak intensity
(CPS/mA) versus the gold concentration (PPM) using different tissue types showed an R2
correlation o f greater than or equal to 0.93, despite having different slopes (0.07330.0856 cps/mA/PPM). We hypothesize that the small variations observed in reported
slopes were attributable to variations in tissue densities given that the regressions were
similar when multiple preparations o f the same tissue type were analyzed. The calculated
concentration values for gold in tumors were similar to the work published by Huang and
colleagues, which used industry standard methods. [30] Commercial laboratories that
employ 1NAA or 1CP-MS to analyze gold concentration report a detection limit in the
low PPB range. This EDXRF analysis method demonstrates a detection limit o f 1.4 ppm
(3o) and a sensitivity o f 0.07126 cps/mA/PPM. This higher detection limit is acceptable
due to the clinical requirements o f rapid results in the PPM range.
The majority o f the problems encountered were due to the presence o f other
elements that spectrally overlapped with one or more o f the peaks o f interest, as seen in
previous work. [82] The zinc KPi peak (9.570 Kev) overlaps the Lai peak for gold (9.712
Kev). Other peaks were explored for potential use; a second peak, the Lp peak ( 11.204-
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11.914 Kev), for gold overlapped the Kai bromine peak (11.906 Kev). The bromine
peak was attributed to the use o f avertin (2-2-2-tribromoethanol) as the anesthesia for this
experiment. The bromine peak was only observed in tissue samples where avertin was
used as the anesthesia. For this reason, the use o f anesthesia may influence the elemental
analysis o f tissues and should be considered among the criteria for selecting anesthesia in
experimental design.

5.5

Elimination of Zinc Peak

The running hypothesis o f the lid o f the machine being the source o f the zinc was
further evaluated after the publication o f the paper. The primary focus o f this evaluation
was to find a cover for the EDXRF sample cups that is x-ray opaque. Multiple potential
covers were evaluated: a glass cup (Figure 5-2), a plastic cup (Figure 5-3), a golf ball
(Figure 5-4), an iron pipe cap (Figure 5-5), and a utility square (Figure 5-6). Due to the
presence o f zinc peaks, the plastic cup and golf ball were eliminated from potential use. It
was decided the plastic cup was not x-ray opaque and the golf ball included zinc in the
core o f the golf ball. Out o f the three remaining items (which appeared to be x-ray
opaque), the utility square was chosen for the ease o f use. It delivered a thin enough layer
placed on the cup to minimize risk o f movement during machine cycling. The evaluation
o f the spectrum was continued and began with an examination o f the potential
contaminants o f the Prolene film (the contaminants o f the utility square were known from
Figure 5-6). Sample spectra were obtained o f cups without and with a Prolene film using
a utility square cover (Figure 5-7 and Figure 5-8, respectively), and no new contaminants
were found. The next stage involved scanning tissue with no exposure to gold and tissue
doped with gold (Figure 5-9 and Figure 5-10, respectively). The Spectrum collected for

both o f these samples demonstrated a zinc peak. This finding demonstrates the zinc is an
endogenous trace element. The search for an x-ray opaque cap was a wasted effort.
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Figure 5-2: EDXRF Spectrum o f a glass cup. Showing an argon peak.
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Figure 5-3: EDXRF Spectrum o f a plastic cup. Showing argon and zinc peaks.
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Figure 5-4: EDXRF spectrum o f a golf ball. Showing titanium and zinc peaks.
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Figure 5-5: EDXRF spectrum o f an iron pipe cap. Showing iron and argon peaks.
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F ig u re 5-6: EDXRF spectrum o f a utility square. Showing argon, lanthanum,
manganese, and iron peaks.
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Figure 5-7: EDXRF spectrum o f an empty EDXRF sample cup with no Prolene film
capped with the utility square. Showing argon and iron peaks.
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Figure 5-8: EDXRF spectrum o f an empty EDXRF sample cup with a Prolene film
capped with the utility square. Showing argon and iron peaks.
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F igure 5-9: EDXRF spectrum o f tumor with no gold exposure on a Prolene film
capped with the utility square. Showing argon, potassium, iron, and zinc peaks.
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Figure 5-10: EDXRF spectrum o f tumor doped to 33 PPM o f gold on a Prolene film
capped with the utility square. Showing argon, potassium, iron, zinc, and gold peaks.

5.6

Review of Specifications

Without this extended effort, the project met the original specifications
demonstrated in Table 5-1. The data from this project was initially presented at the 2012
BMES Annual Meeting on October 27, 2012 in a presentation titled “Real-Time
Measurement o f the Bioavailability Curve o f Experimental Gold Nanorods Towards
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Dose Optimization,’' and is included in a publication titled “Feasibility o f energy
dispersive x-ray fluorescence determination o f gold in soft tissue for clinical
applications”. [83]

Table 5-1: Summary o f CHAPTER 5 specifications.
Specification
Complete sample analysis 12 hours
after collection.

Minimal sample preparation.

As described in materials and methods, the
time needed for all steps combined can
provide analysis in 12 hours.
The materials and methods section describes
the sample preparation. The quick nature o f
the sample preparation (compared to other
methods) was decided to be faster and
simpler. In addition, the required skills are
limited to reproducible pipetting.

CHAPTER 6
USE OF REAL-TIME PHARMACOKINETICS
TO PREDICT TUMOR UPTAKE
OF GOLD NANORODS

6.1

Introduction and Specifications

The work in this chapter involves protocol improvements informed by the work in
CHAPTER 4: Animal Protocol Review Using Gold Nanoshells, and demonstrates the
need for the Mathematical Modeling work in CHAPTER 3. In addition, the initial
experiments demonstrated the need for a rapid elemental analysis system developed in
CHAPTER 5.
Nanoparticle directed photothermal ablation o f tumors relies heavily on the
accumulation o f nanoparticles in target tissues. An appropriate accumulation o f particles
is required for proper thermal confinement and ablation o f the target tumor. Preclinical
studies o f tumor accumulation are being conducted in an effort to more accurately predict
the accumulation o f nanoparticles. This preclinical study in a murine model works to
relate the area under the blood plasma concentration curve to uptake and retention in the
tumor.
Many nanoparticles are currently approved by the FDA or under investigation by
groups seeking FDA approval, despite the fact that various pharmacokinetic parameters
that determine the accumulation and retention o f these particles in the target organ are
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mostly unknown. Some o f these particles include Combidex for MRI contrast, and
NanoTherm Aurimmune, and Auroshell used for cancer therapy. [21] The optimization
o f treatment variables, such as therapeutic dosage, circulation half-life, and clearance
rates, is critical in maximizing the efficacy o f a treatment modality. The majority of
nanorods are removed from the blood by two pathways: opsonization and elimination by
the RES, and accumulation in tumor tissue due to the EPR. [20], [37], [84], [85] These
two being the major pathways o f removal suggests a correlation between tumor uptake
and retention and bioavaibility should exist. The purpose o f the tumored studies is to
correlate standard pharmacokinetic metrics to the uptake and retention o f gold nanorods
in tumors.
This set o f experiments is based a hypothesis that pharmacokinetic metrics will be
a more accurate predictor o f tumor uptake alone and on the following specifications:
•

Blood plasma concentrations will be collected in near real-time.

•

Discrete blood plasma concentrations will be processed quickly (less than
5 minutes) after collection for inclusion in an actively changing onecompartment pharmacokinetic model.

•

Elemental analysis o f tumor tissue is completed in under 12 hours post
experiment. Additional data processing time is limited to one hour after
completion o f instrumentation time.

6.2

Materials and Methods

All o f the studies involve animal work conducted under protocol approved by the
Louisiana Tech University and Nanospectra Biosciences, Inc. Institutional Animal Care

and Use Committee (IACUC). The animals were handled in accordance with the 'Guide
for the Care and Use o f Laboratory Animals’.
All tumored studies involve naive BALB/c females inoculated with 1.5 X 105 (50
ml injection volume) CT26.WT murine colon carcinoma tumor cells (ATCC) were
obtained from NBI. When animals arrived at Louisiana Tech University Center for
Biomedical Engineering and Rehabilitation sciences, the mice were kept in general
animal housing until the tumors were the proper experimental size, approximately 100
cubic centimeters.
6.2.1

Initial Experiments
This study involved the use o f eight naive, tumor inoculated BALB/c female

mice. The mice were divided into two groups: Group A (4.5 pL/g) and Group B (9 pL/g).
This experiment was designed to explore the differences in circulation half-life and other
pharmacokinetic parameters between the two dose groups.
6.2.1.1

Temperature Control. Anesthesia, and Injection
The mice were put in a thirty-six degree Celsius environment (Labnet

International, Inc. Edison, NJ. Model # 21 IDS) for a minimum o f forty-five minutes
prior to injection. The mice were anesthetized using isoflurane anesthesia (given at one
liter per minute at four percent for induction and two percemt for maintenance), and the
nanorods were injected over up to ten minute via tail vein at a rate o f up to 18 pl/min.
Once any procedure was completed, the mouse was returned to animal housing, between
procedures, for the duration o f the accumulation phase.

6.2.1.2

Blood Plasma Concentration Data Collection
Blood plasma concentration data was taken at intervals o f approximately 20

minutes post injection, 90 minutes post injection, end o f the first half life, 1.33 half-lives,
1.66 half-lives, and at the end o f the second half life. These times were based on an
assumed six-hour half-life, and altered if an extremely long or short half-life was noted.
If it was not possible to collect data at those exact times for any reason the data point was
taken early or late to get as close to the correct time as possible. The concentration in the
blood was calculated by using the NanoTracker, and confirmed using an established
ultraviolet-visible spectroscopy (UV/Vis) protocol (APPENDIX A). The blood for the
UV/Vis protocol was collected by snipping the end o f the tail and collecting five micro
liters o f blood using a pipette coated in EDTA, under Isoflurane anesthesia. NanoTracker
points were taken before and after the blood draw.
6.2.1.3

End o f experiment
The mouse was sacrificed when the blood plasma concentration reached an

optical density o f 1±10%. The mouse was sedated using a ketamine and zylazine mixture,
and then sacrificed by exsanguination via cardiac puncture. Liver, kidneys, spleen, tumor,
heart, and lungs were collected for EDXRF analysis.
6.2.1.4

Data Analysis

Data analyzed post experiment to create blood plasma concentration curves using
Microsoft Excel. The Excel spreadsheet was designed to take the raw tabular spectra
from each blood draw and calculate an adjusted optical density for each time point. From
this spreadsheet, the data was plotted (optical density versus time).
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6.2.2

Revised Experiments
This experiment involved seventeen tumor inoculated BALB/c female mice. The

mice were divided into two dose groups (Group A and Group B) to investigate the
differences in pharmacokinetic metrics, blood plasma concentration and tumor uptake
based on injected dose.
6.2.2.1

Temperature Control
The mouse was placed in an environment with an ambient temperature o f thirty-

five degrees Celsius for two and a half hours using a shaking incubator, with the shaker
off (Labnet International, Inc. Edison, NJ. Model # 2 1 1 DS). For at least one hour prior to
the injection, the ambient temperature was increased to thirty-nine degrees Celsius.
During injection and while the mice were under anesthesia the temperature was
controlled using a heating pad (Physitemp Instruments, Inc. Clifton, NJ. Model # TCAT2LV) and/or a space heater for ambient air temperature (Sunbeam Products, Boca Raton,
FL. Model # S F H 1 11)
After the injection, the mouse was returned to the incubator kept in a thirty-nine
degree Celsius environment for the first three and a half hours o f the accumulation phase.
After the first three and a half hours, the mouse was returned to a room temperature
environment for the remainder o f the experiment.
6.2.2.2

Anesthesia and Injection
Intravenous cannulation was established after the mouse was under anesthesia.

Avertin anesthesia (APPENDIX C) was administered by intraperitoneal injection at the
dosage o f 25 micro-liters per gram o f body weight, while the air flow was maintained
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steady at a rate o f one L/min with the help o f an Oxygen concentrator (Invacare Model:
IRC5LX02, Elyria, OH) during the experiment.
The nanorod injection was done by cannulating one o f the lateral tail veins. Once
an intravenous cannula has been established and flushed with saline the NanoTracker was
attached to the tail. The nanorods were injected at a rate o f up to 18 micro-liters per
minute using a syringe pump (New Era Pump Systems Inc., Model#NE-1010). The~100
OD nanorods were intravenously injected at the dosage o f 4.5 pL/gm (Group A) or nine
pL/gm (Group B) body weight at the rate o f up tol 8 pl/min. The NanoTracker was used
to monitor the condition o f the mouse while under anesthesia.
6.2.2.3

NanoTracker Data Collection
The NanoTracker was used to read the blood plasma concentration o f nanorods.

The NanoTracker was attached to the tail o f the mouse in a warm environment, with the
help o f a Physitemp TCAT-2LV controller pad set to 38°C and carefully monitored space
heaters.
Once temperature stabilization was achieved, the probe was placed on the awake
animal’s tail and the NanoTracker was allowed to collect data. Five-second averages o f
the values o f R were computed to assess signal stability.
Data collection was designed around an assumed six-hour circulation half-life o f
the nanorods, and with approximately five data points in the first half-life, two in the
second and one in the third half-life. Data should be collected were close to the following
time points as possible: 5, 45, 120, 240, 360, 450, 720, and 1080 minutes.

6.2.2.4

End o f Experiment
The mouse was sacrificed when the blood plasma concentration reached an

optical density o f one plus or minus ten percent. The mouse was sedated using a ketamine
and zylazine mixture, and then sacrificed by exsanguination via cardiac puncture. Liver,
kidneys, spleen, tumor, heart, and lungs were collected for EDXRF analysis.
6.2.2.5

Data Analysis

The collected data was be sorted by MATLAB code. A code was specifically written
to extract the data points that meet all the criteria for data standards. Anticipating
potential transient problems such as motion artifact or low perfusion, the signal was
deemed acceptable only if the following criteria were met;
•

AC magnitude was in the range o f 10-100 mV peak-to-peak

•

the standard deviation o f R was less than 0.03

•

The heart rate measured on all three channels (660, 805 and 940 nm) were within
ten percent o f each other.

The data extracted from the raw experimental data and the average optical density
value was used to produce a blood plasma concentration curve (using a single decay
exponential model). This curve was used to calculate the area under the curve (AUC),
which was used as a pharmacokinetic parameter in the experiment. In addition, the peak
value and the half-life o f the clearance curve were calculated.
6.2.2.6

EDXRF Tumor Sample Preparation
Using the wet weight o f the tumor, obtained the day o f extraction, 20% (m/m)

KOH was added at the rate o f three pL KOH/mg o f tumor. The tissue was left at room
temperature, in a low speed shaker until all tissue dissolved in the solution. From each
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tumor sample, 30 pL (of tissue + KOH solution) was pipetted in up to three unique
EDXRF cups, as many as the mass o f tumor tissue will allow. The solution was then
dried down in a vacuum oven at 30° C under 15 in Hg vacuum until tissue sample is
completely dry, this normally takes up to four hours. The dried samples were run in the
EDXRF machine (Quant’X, Thermo Electron Corporation) and run each sample with ten
replicates.
The machine calculated a ppm (parts per million) value for the concentration of
gold in the tumor.
6,2,2,7

EDXRF Tumor Sample Data Analysis
The ppm calculations were manually verified by using the calibration set in the

machine. The spectra from the calibration set (of known concentration values) were
extracted and the area under the curve o f the gold L-al peak (9.94 to 9.30 KeV) was
extracted. From these values, the peak intensities were calculated and a calibration curve
was established. The calibration curve compared the peak intensity values (cps/mA)
against known concentration (ppm) values.

6.3

6.3.1

Results

Initial Experiments
The initial experiments demonstrated an average half-life o f 276 and 462 minutes

for group A and B, respectively. Table 6-1 gives the calculated half-life, average, and
standard deviation for each group.
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T able 6-1: Half lives for all mice in study (n=8) by dose group with averages.

Mouse 1
Mouse 2
Mouse 3
Mouse 4

Group A
323
251
287
243

Group B
452
547
389
460

The results o f this study demonstrate a significant difference between the halflives o f Dose Group A (n=4, mean=276.16 min) and Dose Group B (n=4, mean=461.92
min) (T-Test: p-value=0.0025, a=0.05).
6.3.2

Revised Experiments
The results o f the rapid elemental analysis are displayed on a chart with the

EDXRF calibration data (Figure 6-1). The tumor concentration ranged from 6.84-41.49
PPM. Figure 6-2 through Figure 6-9 show scatter plots o f tumor accumulation plotted
versus pharmacokinetic metrics. O f these, the highest R2 correlations came from Injected
dose (Figure 6-5, R2=0.458) and Area under the Blood Plasma Concentration Curve
(Figure 6-2, R2=0.4503). Table 6-2 lists the computed half-lives for all mice in the study,
and shows the large increase in average half-life from 271 minutes (group A) to 408
minutes(group B). The p-values from Table 6-3 demonstrate tumor weight is the only
parameter where we are unable to reject the null hypothesis (the means o f the dose
groups are equal) (a=0.05).
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Table 6-2: Half lives for all mice in study (n = 17). Dose group A (n = 8) and dose
group B (n = 9) with averages and standard deviations.
Group A

Group B

Mouse 1

320

444

Mouse 2

357

313

Mouse 3

205

523

Mouse 4

267

373

Mouse 5

235

300

Mouse 6

281

356

Mouse 7

268

435

Mouse 8

236

478

Mouse 9

449
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Table 6-3: P-values for comparison o f pharmacokinetic and accumulation
parameters between dose groups A and B.
p-value
Concentration (PPM)

0.000129721

AUC (OD*min)

0.000120694

AUMC (OD*MIN2)

4.20157E-05

OD Adjusted Dose

6.24664E-07

injected dose (pL)

5.33305E-08

mean residence time

1.87732E-05

Elimination rate constant

0.00044814

half-life (min)

0.000579249

initial concentration from fit (OD)

0.026590645

Tumor Weight (g)

0.703795196

6.4

Discussion and Review of Specifications

The initial experiments elaborated on problems in the protocol, NanoTracker data
saving problems, found in the experiments discussed in CHAPTER 4: Animal Protocol
Review. Initial intermediate solutions created from the work discussed in Animal
Protocol Review CHAPTER 4 were used in the initial experiments. The final solutions
implemented because o f the previous work and this work are discussed in CHAPTER 4.
In addition to the problems with the NanoTracker data extraction, problems and
delays with the elemental analysis protocols caused the loss o f those tissue samples.
These problems were corrected prior to the beginning o f the revised experiments. The
elemental analysis technique was more thoroughly established prior to beginning o f
experiments. To correct the problems with the NanoTracker data a more structured
method o f saving data was established. Through the initial experiments, we also found a
need for more strict data inclusion rules to be established. In addition the UV/Vis blood
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draws were eliminated from future procedures due to the potential for human error and
the sampling o f large (by % o f total) volumes o f blood without replacement.
6.4.1

Initial Experiments
The half-life data demonstrate an average half-life o f 276 minutes and 462

minutes for dose groups A and B, respectively. After statistical testing (t-test) we were
able to reject the null hypothesis (equal means) with a p-value o f 0.0025 (a=0.05).
6.4.2

Revised Experiments
After analysis o f the concentration o f gold in the tumors the parameter with the

highest correlation (R2=0.4605) is a linear correlation with mean residence time. Other
parameters such as injected dose, area under the blood plasma concentration curve, OD
adjusted dose, area under the first moment curve, initial concentration, half-life, and
tumor weight which have R2 values o f 0.458, 0.4503, 0.4321, 0.4084, 0.3578, 0.2477,
and 0.000007, respectively. These correlations demonstrate the pharmacokinetic
parameters which best predict tumor accumulation are mean residence time, injected
dose, and area under the blood plasma concentration curve.
Each o f these parameters demonstrate a significant difference between dose group
A and dose group B except for tumor weight. This finding is logical because all o f the
other parameters listed involve differences based on given dose, where the tumor weights
were controlled to be similar irrespective to dose group.
A review o f specifications is presented in Table 6-4, and a subset o f this data was
presented at the 2012 BMES Annual Meeting on October 27, 2012 in a presentation titled
“Real-Time Measurement o f the Bioavailability Curve o f Experimental Gold Nanorods
Towards Dose Optimization,” and is a subset o f the data in an in-progress publication
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titled “A Study o f Gold Nanorod Bioavailability and Tumor Uptake in a Murine Model.”
This data was also published in a conference proceedings paper titled “LQR Tracking o f
a Delay Differential Equation Model for the Study o f Nanoparticle Dosing Strategies for
Cancer Therapy”. [79]

Table 6-4: Review o f specifications.
Specification
Blood plasma concentrations will be
collected in near real-time
Discrete blood plasma
concentrations will be processed
quickly (less than 5 minutes) after
collection for inclusion in an actively
changing one-compartment
pharmacokinetic model.
Elemental analysis o f tumor tissue is
completed in under 12 hours post
experiment. Additional data
processing time is limited to one
hour after completion o f
instrumentation time.

Status
Specification met through elimination of
blood draws and use o f NanoTracker
Specification met through use o f MATLAB
code designed to streamline and create
reproducible data analysis

This specification was met using a rapid
elemental analysis protocol discussed in
CHAPTER 5.

CHAPTER 7
OBSERVATION OF COFACTORS ON
PREDICTION OF TUMOR UPTAKE
OF GOLD NANOSHELLS

7.1

Introduction and Specifications

An initial analysis using AUC to predict uptake (CHAPTER 6) was unsuccessful
and had large outliers (R2=0.32, n=8). Recent collaborative modelling efforts examined
the relationship between extravasation and anatomical and physiological variables. [28]
The physiological variables evaluated in the model include vessel-wall pore size,
perfusion, and blood pressure, with flow rate held constant. Based on this modeling
effort, some o f these parameters have been collected to study in an effort to control or
improve the predictability o f tumor accumulation. Hyperthermia (38+ deg. C) allows for
the modulation o f pore size and flow rate in the subdermal ectopic tumor model used.
[76] Particle size or coatings were not modified because o f current status in clinical trials.
Blood pressure was not chemically altered due to a fear o f side effects, but was monitored
due to a concern that pressure may be modified during the injection phase and early in the
accumulation phase due to the injected volume or rate o f infusion. [86]
This study was designed to test preliminary protocols to monitor mouse blood
pressure, core body temperature, and tumor perfusion. The retrospective review o f the
preliminary protocols should include review o f the protocols for feasibility and ability to
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implement the protocol during the experiment, and determine the efficacy o f the current
protocol.

7.2

Materials and Methods

All o f the studies involve animal work conducted under protocol approved by the
Louisiana Tech University and Nanospectra Biosciences, Inc. Institutional Animal Care
and Use Committee (IACUC). The animals were handled in accordance with the 'Guide
for the Care and Use o f Laboratory Animals’.
7.2.1

Investigation o f Cofactors
Nine BALB/c female mice were inoculated with 1.5 X 105(50 ml injection

volume) CT26.WT murine colon carcinoma tumor cells (ATCC). Pre-experiment
ambient temperature protocols were followed: 35°C for two and a half hours followed by
a minimum o f one hour at 39°C immediately prior to injection. Experiment groups were
divided in two groups a “hot” group to remain at 39°C until the end o f experiment, and a
“cold” group to return to room temperature (20-25°C) after injection. At a minimum o f
one hour prior to injection thermal images o f the tumor were collected. The mice were
injected with PEGylated gold nanoshells (four and half pL/g 100 OD). Blood plasma
concentration observations were collected using the NanoTracker to develop a blood
plasma concentration curve and develop pharmacokinetic models. Blood pressure and
rectal temperature was collected at each NanoTracker reading. Elemental analysis o f the
tumor samples were conducted using a rapid energy dispersive x-ray fluorescence
technique. [83]
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7.2.2

Intravenous Catheters and Cannulation
Intravenous cannulas ware made using two French Polyurethane Catheter tubing

(Access Technologies, Skokie, IL Cat. No BC-2P). On one end, used as the needle for
vascular access, a 28 gauge needle was removed from an insulin syringe (Tyco/
Healthcare '/* mL 28G x 'A” insulin syringe REF # 1188528012, VWR Cat. # 84009-742)
and attached to the tubing. On the other end o f the tubing a 27 gauge needle (Becton
Dickinson 27G x 'A” REF 305109, VWR Cat. # BD305109) was added for slip tip or luer
lock access to the cannula. Injection solution was loaded in a one-milliliter insulin
syringe (Becton Dickinson one-milliliter syringe REF 329650, VWR Cat. # BD329654).
Injection volume and rate were ensured using a syringe pump (New Era Pump Systems,
Inc. Farmingdale, NY. Model # NE-1010).
7.2.3

Temperature Control
Temperature regulation o f the mice prior to injection was achieved using a

shaking incubator, with the shaker o ff (Labnet International, Inc. Edison, NJ. Model #
211DS). During injection and while the mice were under anesthesia the temperature was
controlled using a heating pad (Physitemp Instruments, Inc. Clifton, NJ. Model # TCAT2LV) and a space heater for ambient air temperature (Sunbeam Products, Boca Raton,
FL. Model # S F H 1 11).
7.2.4

Gold Nanoshells
PEG modified gold nanoshells (FTS20130919) were obtained from NBI. The

absorption spectra o f the nanoshells was obtained using a UV/Vis spectrophotometer
(Beckman Coulter DU 800 Brea, CA.). A one percent dilution o f nanorods was made in
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DI water to obtain the absorbance at 600, 805, and 940 nm. These values are required as
input values o f the NanoTracker to ensure proper calculations.
7.2.5

Blood Plasma Concentration Observations
Blood plasma concentration was observed at intervals o f approximately: 5, 45,

120, 240, 360, 450, and 720 minutes post injection. These times were based on an
assumed six-hour half-life, and altered if an extremely long or short half-life was noted.
If it was not possible to collect data at those exact times for any reason the data point was
taken early or late to get as close to the correct time as possible.
Blood plasma concentration was collected using the NanoTracker. Data was
saved in a raw data directory with the name o f the file corresponding to the minutes after
injection when data save started. The only metric able to me monitored quickly as the
data was passing on the screen was the standard deviation o f the two ratios. An effort was
made to collect ten “good” data points to ensure 30 seconds o f good data (30 seconds is
equal to six - five second data points). The required six points was given an extra four
points in case some o f the other data metrics were not met and some had to be eliminated.
All save files were processed by MATLAB code, and if irregularities were found the data
was collected again.
7.2.6

One-Compartment Pharmacokinetic Model
Each saved data file (per observation) was processed through MATLAB

(APPENDIX B: Sample MATLAB processing code). The MATLAB code was able to
provide filtering for noise and unreliable data points. In addition, the MATLAB code
created data files and exported charts. The files and charts included metrics o f standard

one-compartment pharmacokinetic models including: exponential trend line, r2, half-life,
area under the curve, area under the first moment curve, and mean residence time.
7.2.7

End o f Experiment and Animal Termination
The end o f experiment was determined to be when the blood plasma

concentration reached one optical density plus or minus ten percent. The animal was
sacrificed by exsanguination via cardiac puncture, under heavy anesthesia (an
intraperitoneal injection o f a ketamine (100mg/ml)/zylazine (lOOmg/ml) mixture at 0.1
ml/lOg o f body weight). The tumor was collected for elemental analysis; the liver, spleen
kidneys, heart, and lungs were collected for potential elemental analysis. [83]

7,3

Results

The tumor accumulation for hot mice ranged from 9-12.6 PPM and the cold mice
were 21.9 and 12.4 PPM (shown in Table 7-1).
Table 7-2 elaborated further on standard pharmacokinetic metrics used for
evaluation o f each injection. The core body temperature and systolic blood pressure
measurements did not demonstrate a significant difference between (p-values o f 0.14 and
0.065, respectively) the two different test groups. The data is demonstrated in tukey plots
for core body temperature (Figure 7-1) and systolic blood pressure (Figure 7-2). The
NanoTracker data was used to construct all and average data graphs for hot (Figure 7-3
and Figure 7-4) and cold mice (Figure 7-5 and Figure 7-6). These figures demonstrate the
NanoTracker data processed in the form o f a rapidly produced one compartment
pharmacokinetic model.
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T able 7-1: Tumor Accumulation by Mouse. Average tumor accumulation is 13.1 ± 5.2
PPM.
Experimental Group
Hot
Hot
Hot
Cold
Cold

Mouse Number
2013121OA-4
20131210B-0
2013121 OB-1
20131210A-2
20131210A-5

Tumor Accumulation (PPM)
9.0
9.3
12.6
21.9
12.4

Table 7-2: Pharmacokinetic Metrics by Mouse. AUC- Area Under the blood plasma
concentration Curve, SBP- maximum observed Systolic Blood Pressure, DBPmaximum observed Diastolic Blood Pressure, Tern- maximum oberved core body
Temperature, MRT- Mean Residence Time, T 1/2 - circulation half-life, a- model
predicted initial concentration, a- model predicted elimination rate constant, r2- model
correlation coefficient.
M ouse Number
& Group

MRT

a

r2

SBP

DBP

Temp

A -l Hot

131.8

133

69

35.7

56.1

368

1.25

-0.002

0.88

A-4 Hot

244.3

132

106

38.7

79.9

183

1.8

-0.004

0.65

B-0 Hot

985.3

144

117

38

250.5

414

2.58

-0.002

0.92

B -l Hot

271.1

111

62

38.6

110.3

362

1.41

-0.002

0.53

B-2 Hot

567.3

129

96

38.2

167.9

425

2

-0.002

0.98

A-2 Cold

447.0

118

82

38.8

131.6

266

2.1

-0.003

0.95

AUC

a

T1 /2

A-3 Cold

391.3

160

87

38.1

125.1

217

1.99

-0.003

0.97

A-5 Cold

586.0

117

87

38.7

160.9

241

2.46

-0.003

0.86

B-3 Cold

781.5

149

91

32.8

167.7

248

3.19

-0.003

0.89
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Figure 7-1: Tukey boxplot, with outliers (o). Individual temperature observations are
shown (X). The average core temperature was 36.46 ± 1.26 °C and 37.04± 1.56 °C for
hot and cold mice, respectively. A student’s t-test demonstrated a p-value o f 0.140
(a=0.05).
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Figure 7-2: Tukey boxplot, with outliers (o). Individual systolic blood pressure
observations are shown (X). The average systolic blood pressure was 115 ± 16 mmHg
and 106 ± 18 mmHg for hot and cold mice, respectively. A student’s t-test
demonstrated a p-value o f 0.065 (a=0.05).
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Figure 7-4: Average Data Chart for Mouse 2 0 13 12 1OB-1: This chart contains an
averaged blood plasma concentration for each representative time point collected for
Mouse 20131210B-1, a member o f the hot mouse group. The chart also includes
values for the exponential fit, half-life, AUC, AUMC, and MRT.

Figure 7-5: All Data Chart for Mouse 20131210A-5: This chart contains every
NanoTracker point collected for Mouse 20131210A-5, a member o f the cold mouse
group.
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Figure 7-6: Average Data Chart for Mouse 2013121OA-5: This chart contains an
averaged blood plasma concentration for each representative time point collected for
Mouse 20131210A-5, a member o f the cold mouse group. The chart also includes
values for the exponential fit, half-life, AUC, AUMC, and MRT

7.4

Discussion and Review o f Specifications

The hyperthermia protocol was determined to have no effect on the core body
temperature o f the animal. The average core body temperature o f the “hot” group was
lower than the average temperature o f the “cold” mice. The student’s t-test comparing the
hot and cold groups revealed a p-value o f 0.140. Based on the p-value, we are unable to
reject the null hypothesis; the means are not dissimilar. This finding shows that we are
not changing the core body temperature using the current ambient temperature protocol.
The thermal imaging perfusion protocol was indeterminate, and is currently being
redesigned using new instrumentation (Laser Doppler Flowmetry). Future studies (using
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Laser Doppler Flowmetry) will have to evaluate the use o f this hyperthermia protocol to
effect tumor perfusion. The average accumulation values o f 13.05 ± 5.23 PPM for the
five mice in this data set, and 11.31 ± 5.16 PPM for the eight mice in the 1x data set from
zero are very similar. These data sets also produce a p-value o f 0.574 when compared
using a student’s t-test. The cofactors data set o f five mice is too small for parametric
testing to provide meaningful results, but these values suggest the two data sets are not
dissimilar. This comparison suggests the hyperthermia protocol may not be affecting
tumor perfusion. The monitoring o f blood pressure was determined to be unnecessary.
The blood pressure data did not support a difference (based on student’s t-test) between
the systolic blood pressure o f the two groups. In addition, the average systolic blood
pressure reading is 110.46 ± 17.22 mmHg. No mouse trended to have higher systolic
blood pressures, mice saw transient spikes in blood pressure where high or low values
were never seen for more than one point in a row. I was unable to find any trending with
time our mouse to describe the behavior o f systolic blood pressure. The lack o f definitive
trends, and the timing difficulty o f collecting blood pressure data at each blood plasma
concentration reading lead to recommendations to reduce the number o f blood pressure
readings. The blood pressure readings should be taken at the beginning o f the experiment
or on multiple days before the experiment to exclude mice with chronic hypertension.
A summary o f protocol problems and solutions is presented in Table 7-3, and a
subset o f this data was presented (presentation title: “The Use o f Real-Time Optical
Feedback to Improve Outcomes”) at Photonics West BiOS on February 2, 2014, with an
associated conference proceedings publication. [86]
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Table 7-3: Summary o f observed protocol problems and solutions.
Observed Problem
Blood pressure measurements take
too long and create delays in data
collection
Ambient temperature protocols do
not change the core body
temperature o f the mouse
Thermal imaging did not show
useable correlations
Blood pressure measurements did
not show trends between mice or
groups

Solution
Take fewer blood pressure measurements
during accumulation phase.
Discontinue use o f protocols and consider
chemically induced systemic hyperthermia
Consider new instrumentation: Laser Doppler
Flowmetry
Suggests lower need for monitoring during
accumulation phase.

CHAPTER 8
RETICULOENDOTHELIAL SYSTEM
BLOCKADE AND REDOSING
OF GOLD NANORODS
IN A MURINE
MODEL

8.1

Introduction and Hypothesis

Several types o f nanomaterials are under investigation in preclinical and clinical
trials for use in cancer therapies. Current medical-grade particles are constructed from a
variety o f materials including lipids, polymers, and metals, [21] and are routinely
delivered intravenously for passive or active accumulation in tumor tissue. [20]
Accumulation via the vascular route increases as the nanoparticle circulation time
increases and the nanoparticle circulation time increases by discouraging their removal
by the reticuloendothelial system (RES). The high removal rate observed by the RES of
charged and hydrophobic particles, [27] which is a requirement o f a stable colloidal
system, creates a need to mask the charge by adding a surface coating for nanoparticle
therapies to be most effective.
A common surface coating for stealth nanoparticles is polyethylene glycol (PEG)
which uses steric hindrance to provide for colloidal stability and to prevent the adsorption
o f opsonins. [27] PEG, in a liposome formulation, provides a significantly longer half-life
compared to an unshielded type, but some groups show this advantage may diminish in
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subsequent injections. [46], [47] Some studies point to PEG as a source o f the accelerated
blood clearance (ABC) phenomenon and found that PEG acts as a type-two T cellindependent antigen. [48], [50] Ichihara and colleagues suggest that the mechanism
responsible for ABC could be anti-PEG IgM [50]; this theory is corroborated by studies
which identified a soluble serum factor as a mediator from serum transfusion studies.
[46], [47]
The Kupffer cells in the liver provide a major removal route o f nanoparticles by
the RES. Multiple agents have been evaluated to suppress the actions o f the Kupffer cells.
Particles cleared by the RES which can utilize this adjuvant therapy include types of
liposomes, [87] iron oxide nanoparticles, [88] gold nanoshells, [89] gold nanorods, [90]
quantum dots, [91] dendrimers, [92] micelles, [93] and carbon nanotubes. [90] Souhami
and colleagues used dextran sulfate or carbon as a blockade agent and demonstrated
limited success and utility at decreasing clearance. [94] Van Rooijen and colleagues
compared the efficacy o f liposome-encapsulated clodronate, propamidine, and
ethylenediaminetetraacetic acid. [95] The results o f their study demonstrated propamidine
was the most effective followed by clodronate. [95]
In contrast to the toxic nature o f other available RES blockade agents, XCarrageenan demonstrated utility in suppression o f hepatic phagocytosis and was
designated as Generally Recognized as Safe (GRAS) by the FDA.[96] This GRAS
designation means that companies might not be required to complete extensive and costly
studies on X-Carrageenan to prove safety. X-Carrageenan could be used with particles
currently under investigation as an adjuvant therapy; developers would not have to restart
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the trials o f their particles due to changes with the surface modification, saving time and
money.
This study evaluates RES blockade using X-carrageenan intravenously
administered immediately prior to the injection o f PEGylated gold nanorods (NRs). The
quantifiable extension o f their circulation time was measured using the NanoTracker.
[23], [36] The real-time observations were used to create the population pharmacokinetic
(PK) model and calculate PK metrics, thus pointing to the potential clinical utility o f the
optical sensing method.
This study is hypothesis driven work. The hypothesis o f this experiment is the use
o f an adjuvant RES blockade agent will be able to increase the circulation half-life of
PEGylated gold nanorods.

8.2
8.2.1

Materials and Methods

Overview
All animals were handled and cared for in accordance with the Louisiana

Tech University Institutional Animal Care and Use Committee. Ten BALB/c female mice
were initially assigned one o f three groups (A, B, or C). In subsequent weeks, some mice
were moved between groups B and C and then, after week 3, mice in groups B and C
were combined to form group D, as shown in Figure 8-1: Flow chart describing the flow
of protocols.. NRs were prepared by Nanospectra Biosciences, Inc. (NBI, Houston, TX)
using the methods described by Goodrich and colleagues. [37] Post-manufacturing
characterization was performed at NBI prior to shipment (shown in Table 8-1); the
extinction spectrum o f the gold nanoparticles was measured using a UV-Vis
spectrophotometer prior to the injection to quantify concentration and stability.
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Intravenous injections and blood plasma concentrations were monitored using the
NanoTracker, and a population pharmacokinetic (PK) model was created from that data.

Group A1

G roup B1

Group C 1
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i .....
Group A7

..........
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i .....
Group D5

F igure 8-1: Flow chart describing the flow o f protocols.

Table 8-1: Post-Manufacturing Characterization.
Approximate Size (TEM)
Absorbance at Peak
Absorbance at 800 nm
Surface Zeta Potential
CTAB Concentration

8,2,2

8 x 24 nm
91.7 OD (5), 762 nm
81.1 OD
-1 1.2mV
60 pM

Injection
Prior to injection, the animals were kept in an incubator set at 37°C for a

minimum o f 30 minutes to facilitate intravenous cannulation. Isoflurane inhalation
anesthesia was used to immobilize the animal for injection and to assist with the
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collection o f the first OD reading. NR (NB1 Batch TR20110221) injections were
administered via intravenous cannulation o f the tail vein. The majority o f injections were
delivered at a rate o f 20 pL/minute by syringe but nine (o f 35) injections were made at 40
pL/minute. Optical density data was collected using the NanoTracker. Data was then
processed in MATLAB to provide data for pharmacokinetic analysis.
8.2.3

Dose o f k-Carrageenan
A dose o f 25 mg/kg body weight was reported [97] to produce sufficient

depression o f RES functions. The dose was increased to 50 mg/kg to increase the
likelihood o f a statistically valid result in a small sample group, k-carrageenan (Sigma
22049-5G-F, CAS 9064-57-7) was added to mammalian normal saline to create a stock
solution o f 8 mg/mL (chosen due to solubility o f A-carrageenan in saline) and the volume
o f the stock solution injected was 6.25 pL/g o f A.-carrageenan.
8.2.4

Experimental and Control groups
Group A mice were given a standard dose o f X-carrageenan (50 mg/kg)

immediately prior to a standard injection o f gold NRs (4.5 pL/g o f 100 OD NRs). Group
B mice received a pre-injection o f normal saline equal in volume to that o f a standard Xcarrageenan dose immediately prior to a standard NR injection. Group C mice received a
standard NR injection. Mice could switch between groups B and C on a weekly basis, as
needed. Group D mice received a standard injection o f ^.-carrageenan immediately prior
to a standard NR injection; Group D mice were originally participants in groups B and/or
C. Toxicity was not studied during these experiments; however, all animals survived at
least 60 days after their last involvement in this study at which point they were assigned
to other experimental protocols.
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8.2.5

Data collection
Blood plasma concentration in OD was collected using the MWPPG[23], [36] at

intervals o f approximately: 5, 45, 120, 240, 360, 450, and 720 minutes post injection (see
Yendluri 2014 for full blood plasma concentration curves). [98] These times were based
on an assumed six-hour half-life, and altered if an extremely long or short half-life was
noted. If it was not possible to collect data at those exact times for any reason the data
point was taken early or late to get as close to the correct time as possible.
8.2.6

Population Pharmacokinetics
The real-time blood plasma concentration observations were used to create a

population PK model to quantify the effect o f X-carrageenan on the circulation o f gold
NRs. The injected dose was changed from units o f pL injected volume to pg o f injected
gold by multiplying the injected volume by a factor o f 2.79 pg/pL for a 100 OD solution.
The blood plasma concentration data was changed from units o f OD to units o f pg/pL by
multiplying blood plasma concentration in OD by 0.0279 pg/pL per 1-OD solution, as
provided by NB1.
The PK model was fit to blood plasma concentration data in a Bayesian manner
using the WinBUGS 1.4.3 [99] software called from R using the R2WinBUGS package.
[100] Five chains were used for each analysis with each chain having a burn-in period o f
10,000 iterations, a post bum-in period o f 10,000 iterations, and every fifth sample was
retained. This method results in a total sample o f 10,000 iterations. Gelman-Rubin
diagnostics were used to confirm convergence o f the PK model.
The covariate free PK model compartment structure and variability models were
selected by comparing the deviance information criterion o f PK models. The following
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model components were evaluated: one- and two-compartment structures; absorption;
inter-mouse variability and inter-trial variability on PK variables (e.g. clearance and
volume o f distribution); and additive, proportional, and combined residual error models.
Non-informative normal distributions were used as the prior distributions for PK model
parameters. Inverse gamma distributions were used for the precision o f normally
distributed errors.
After selection o f the base model, covariate effects o f pharmacokinetic model
parameters were tested using a backwards elimination technique. The effects o f (1)
receiving /.-carrageenan (yes/no) on clearance and/or volume o f distribution, (2)
receiving a pre-injection bolus (yes/no) on clearance and/or volume o f distribution, (3)
number o f previous injections on clearance (Groups B & C only), and (4) an additive
model o f weight on clearance and volume o f distribution were tested. Covariate effects
whose 95% credible intervals (CrI) did cross zero were eliminated one-at-a-time until all
remaining covariate effects were significant.
The final PK model was used to calculate the circulation half-life and area under
the blood plasma concentration versus time curve (AUC) for each mouse trial. A t-test
was used to compare the half-life and AUC for mice who received a pre-injection o f Xcarrageenan (Groups A &D) with mice that did not (Groups B & C). A P-value less than
0.05 was considered statistically significant.

8.3

Results

A one-compartment model with intravenous injection, inter-trial variability on
clearance and volume o f distribution, and a proportional error model best fit the data.
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Two significant covariates were identified: the effect o f pre-injection o f carrageenan on
clearance rate and pre-injection bolus on volume, shown in Table 8-2.

Table 8-2: Population pharamcokinetic parameters for all trials (n=35).
Pharmacokinetic
Parameter
(95% Credible Interval)
Clearance
... Population Median, No.Carrageenan (Groups: B &C)
... Population Median, Carrageenan (Groups: A & D)
... Inter-Trial Variability
Volume o f Distribution
... Population Median, No Bolus (Group: C)
... Population Median, Bolus (Groups: A, B, & D)
... Inter-Trial Variability
Residual Variability

18.9(15.9-22.6) pL/min
11.2 (8 .8 - 13.9) pL/min
5.1 (3.4 - 7.8) pL/min
3,189 (2,392 - 3,906) pL
4,180 (3,784 - 4,587) pL
1,041 (772-1,420) pL
14.9% (13.7-16.3% )

X-Carrageenan decreases the median clearance rate from 18.9 (15.9 - 22.6)
pL/min to 11.2 (8.8 -13.9) pL/min, Table 8-2. This decrease results in extending the
mean half-life from 160 ± 22 minutes (Groups B & C) to 264 ± 73 minutes (Groups A
&D), p<0.01, and raising the AUC o f PEGylated gold NRs from 506 ± 142 OD*min
(Groups B & C) to 893 ± 324 OD*min (Groups A & D), p<0.01 demonstrated in Figure
8-2. These findings support the previously reported use o f ^.-carrageenan as a transient
RES blockade agent, and extend the circulation o f PEGylated gold NRs. Table 8-3 shows
the average half-life and AUC values for each sub-group o f mice in the experiment.
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Figure 8-2: Tukey boxplot, with individual trials shown (X). Carrageenan- Groups A
& D, No.Carrageenan- Groups B & C.
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Table 8-3: Half-life and AUC for each group.
Bolus Type
l-C

Saline

None
l-C

Group
A1
A3
A7
B1
B2
B3
Cl
C2
C3
D1
D5

ti /2 (mins)
mean ± stdev
358 ± 53
219 ± 47
173 ± 11
140 ± 19
167 ± 2 0
161 ± 7
190 ± 31
145 ± 11
161 ± 2 6
245 ± 42
257 ± 47

AUC (OD*min)
mean ± stdev
1,301 ±255
595 ± 232
570 ± 5 3
4 3 5 ± 103
469 ± 93
414 ± 8 0
773 ± 17
487 ± 9
5 5 8 ± 193
891 ± 166
8 5 5 ± 143

n
5
4
2
3
3
3
2
2
2
4
5

The pre-injection bolus is associated with a significant increase in the volume o f
distribution. In the trials without a pre-injection bolus the median volume o f distribution
was 3,198 (95% Crl, 2,392 - 3,906) pL, and in mice with a pre-injection the median
volume o f distribution was 4,180 (95% Crl, 3,784 - 4,587) pL.
Some additional observations between groups are note-worthy although the small
sample size o f sub-groups prohibits rigorous statistical analysis. The initial injection
following ^.-carrageenan pre-injection (A 1) appeared to demonstrate a higher AUC value
(1,301 OD*min) than the subsequent injections (A3= 595, A7=570 OD*min). This
observation seems to support a 4-week redosing cycle similar to PEGylated liposomes as
reported by Dams and colleagues. [47] When /.-carrageenan is given to mice with
previous NRs exposure, but not previous /,-carrageenan exposure, the AUC increased to
near baseline levels (from B2/B3/C2/C3= 474±102 OD*min to D l= 891±166 OD*min),
shown in Figure 8-3. In addition, while the PK model did not show a significant redosing
effect in groups B & C, there was a trend toward an increase in clearance with redosing
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Figure 8-3: Tukey boxplot, with outliers (o). Individual subjects are shown (X).
These groups demonstrate the ability o f X-carrageenan to raise the AUC after multiple
exposures to PEGylated gold NRs.

8.4

Discussion

The findings o f this study demonstrate the utility o f ^.-carrageenan in increasing
the circulation half-life and AUC o f PEGylated gold NRs. In addition, the use o f X-
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carrageenan after a series o f NR injections was able to increase AUC values to be similar
to the AUC o f naive injections. These findings are noteworthy for investigators who wish
to achieve the longer circulation times without particle modification, or who wish to use a
series o f nanoparticle injections.
One finding o f note is the significant change in volume o f distribution with a pre
injection bolus. This finding is important because o f the positive correlation o f half-life
with volume o f distribution; this correlation means an increase in volume o f distribution
will increase the half-life. A potential for increase in half-life caused by an increase in
volume o f distribution should be considered during experimental design; investigators
should be mindful o f pre-injection and injection volumes. Both volumes should be
minimized to avoid unnecessary increase in circulation half-life, especially in small
animals where small injection volumes are non-negligible relative to the volume o f
distribution.
A previous study demonstrated an approximated 15% decrease in blood
clearance, which suggests a limited utility o f RES blockade. [94] However, the current
study demonstrates a 59.3% decrease in clearance using a different blockade agent (kcarrageenan) and using metal nanoparticles in place o f liposomes. This demonstrates that
RES blockade is a viable mechanism for prolonging the circulation o f nanoparticles.
The study design demonstrates the ability to observe changes in volume of
distribution based on pre-injection bolus by creating an appropriate number and style o f
control groups. One limitation o f this study is the small sample size in each group. These
sample sizes were selected to demonstrate feasibility o f X,-carrageenan with the minimal
number o f animals, and limits the ability to analyze secondary effects such as those noted
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as “observations”. These observations will require additional testing to confirm the
results reported here. In addition, the dosage and dosing strategy will also require further
experimentation to optimize. A 50 mg/kg dose o f X-carrageenan was used in this study
but the effects on RES blockade and redosing o f different /.-carrageenan doses is
unknown. No deleterious effects were observed from the use o f X-carrageenan, and all
mice survived though 60 days post study when they were assigned to new protocols.
Although the injection rate was double the intended rate (40 pL/min vs. 20
pL/min) for 9 o f the 35 injections, because the pharmacokinetic model accounts for the
rate o f the injection, these deviations are accounted for the pharmacokinetic analysis and
do not affect these results. Also, because the time required for all injections (2.5 or 5
minutes) is relatively short compared to the half-life o f the NRs (-200 minutes), the
effect on the actual OD measurements is minimal.
The same amount of NRs were delivered for all trials and both injection rates are
reasonable for mice so physiological differences in the mice (e.g., blowout) at the higher
injection rate were neither expected nor observed.
RES blockade, using an agent such as ^.-carrageenan, will cause a significant
increase in the circulation time and exposure o f gold nanorods, which could augment
therapeutic efficacy. Future work might seek to establish use and safety guidelines for
the intravenous use o f k-carrageenan or identify other viable non-toxic agents for
blockade.
This data was presented (presentation title: “The Use o f Real-Time Optical
Feedback to Improve Outcomes”) at Photonics West BiOS on February 2, 2014, with an
associated conference proceedings publication, [86] and is the data set for an in-progress
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publication titled “Suppression o f the Reticuloendothelial System Using k-Carrageenan
to Prolong the Circulation o f Gold Nanoparticles”
8.4.1

Summary

1. X-carrageenan is generally recognized as safe by the FDA
2. X-carrageenan increases the circulation time and AUC o f PEGylated gold
nanorods, at a higher rate than predicted by previous studies.
3. Increased AUC and circulation time after previous exposure to PEGylated
nanoparticles suggests utility to prophylactically minimize ABC.
4. This adjuvant therapy could assist with increasing circulation time and exposure
o f particles without disrupting experimental trials already underway.
5. Pre-Injection boluses and large injections can increase volume o f distribution and
therefore increase circulation half-life.
RES blockade should be effective for all nanoparticles cleared by the RES.

CHAPTER 9
INJECTION NORMALIZATION

9.1

Introduction and Specifications

One noticeable difference in each injection o f nanoshells and nanorods in the
large disparity o f the initial concentration noticed after injection (noticeable in the data
from
Table 7-2 and Table 8-3, and the graphs in CHAPTER 6 and APPENDIX E). One
theory regarding the large disparity in half-lives and clearance involves the observed
differences in maximum blood plasma concentration. The specification o f this work is to
achieve a reproducible maximum blood plasma concentration ± 0.05 OD.

9.2

Methods

The desire to fix this disparity for future testing o f importance led to this body o f
work to create a more reproducible injection. Three methods have been considered and
tested: equal volumes, 70/30, and rate modified. The equal volumes involved injections
o f the same volume regardless o f the weight o f the mouse (this would completely ignore
the inter-mouse variability on volume o f distribution). The 70/30 method would use basic
volume calculations using Eq. 9-1 (where Cx is the concentration o f solution one and two,
and Vx is the volume o f solution one and two) to calculate an injection volume and inject
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70% o f that volume. Following a blood plasma concentration reading, the remaining
“30%” was injected to appropriately hit a blood plasma concentration target (dose is not
conserved).
CiVi = C2V2

Eq.9-1

A sister “Stair Step” protocol where “ l/8x” injections were given until close to the target
blood plasma concentration when smaller injections could be given at the discretion o f
the researcher. The final method was designed to inject nanoshells or nanorods until the
desired blood plasma concentration was observed (dose is not conserved). The rate is
adjusted between ten and 20 pL/min at the discretion o f the researcher to ensure the
target ±0.05 OD is met.
All o f the studies involve animal work conducted under protocol approved by the
Louisiana Tech University Institutional Animal Care and Use Committee (IACUC). The
animals were handled in accordance with the ‘Guide for the Care and Use o f Laboratory
Animals’.
9.2.1

Intravenous Catheters and Cannulation
Intravenous cannulas ware made using two French Polyurethane Catheter tubing

(Access Technologies, Skokie, IL Cat. No BC-2P). On one end, used as the needle for
vascular access, a 28-gauge needle was removed from an insulin syringe (Tyco/
Healthcare 'A mL 28G x VS” insulin syringe REF # 1188528012, VWR Cat. # 84009-742)
and attached to the tubing. On the other end o f the tubing a 27 gauge needle (Becton
Dickinson 27G x VS” REF 305109, VWR Cat. # BD305109) was added for slip tip or luer
lock access to the cannula. Injection solution was loaded in a one mL insulin syringe
(Becton Dickinson 1 mL syringe REF 329650, VWR Cat. # BD329654). Injection
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volume and rate were ensured using a syringe pump (New Era Pump Systems, Inc.
Farmingdale, NY. Model # NE-1010).
9.2.2

Temperature Control
Temperature regulation o f the mice prior to injection was achieved using a

shaking incubator, with the shaker off (Labnet International, Inc. Edison, NJ. Model #
211DS). During injection and while the mice were under anesthesia the temperature was
controlled using a heating pad (Physitemp Instruments, Inc. Clifton, NJ. Model # TCAT2LV) and a space heater for ambient air temperature (Sunbeam Products, Boca Raton,
FL. Model # S F H 1 11).
9.2.2.1

Blood Plasma Concentration Observations
Blood plasma concentration was collected using the NanoTracker. Data was

saved in a raw data directory named “injection”. The file was imported to Microsoft
Excel for manual filtering to exclude data that does not meet data standards. Graphs o f
the injections curves were then plotted in Microsoft Excel.
9.2.3

One-Compartment Pharmacokinetic Model
Each saved data file (per observation) was processed through MATLAB

(APPENDIX B: Sample MATLAB processing code). The MATLAB code was able to
provide filtering for noise and unreliable data points. In addition, the MATLAB code
created data files and exported charts. The files and charts included metrics o f standard
one-compartment pharmacokinetic models including: exponential trend line, r2, half-life,
area under the curve, area under the first moment curve, and mean residence time.
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9.3
9.3.1

Results

Equal Volumes

The approximate maximum blood plasma concentration for the equal volumes
was demonstrated to range from two and one tenth to three and one tenth OD,
demonstrated in Table 9-1. Figure 9-1 through Figure 9-7 are the injection profile for
each injection given under this protocol.

Table 9-1: Maximum blood plasma concentrations for equal volumes experiments.
Figure
Figure 9-1
Figure 9-2
Figure 9-3
Figure 9-4
Figure 9-5
Figure 9-6
Figure 9-7

Approximate Max Blood Plasma (OD)
2.8
2.6
2.4
2.4
2.1
3.1
2.7
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Figure 9-1: Blood Plasma Concentration Curve Mouse A Equal Volumes Injection 1.
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Figure 9-2: Blood Plasma Concentration Curve Mouse A Equal Volumes Injection 2.
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Figure 9-3: Blood Plasma Concentration Curve Mouse B Equal Volumes Injection 1.
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Figure 9-4: Blood Plasma Concentration Curve Mouse B Equal Volumes Injection 2.
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Figure 9-5: Blood Plasma Concentration Curve Mouse 20140728B-0 Equal Volumes
Injection.
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Figure 9-6: Blood Plasma Concentration Curve Mouse 20140728B-2 Equal Volumes
Injection.
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F ig u re 9-7: Blood Plasma Concentration Curve Mouse 20140728B-3 Equal Volumes
Injection.
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9.3.2

Step Injections

Table 9-2 shows a sample worksheet for the how calculations were made in the
70/30 step injection with the observed injection profile shown in Figure 9-8. The
injection profile o f the l/8x stair step injection is shown in Figure 9-9.

Table 9-2: Mouse 20140728B-1 Stair Step Worksheet.
Mouse #

20140728B-1

70% Volume Target

76.384

Date

2014-11-1821:38

70% OD Target

3.85

Mouse Weight

24.8

70% OD Observed

3

Mouse Blood Volume

1984

% Observed

77.92%

Target OD

5.5

Solution OD

100

30% Volume Target

32.736

Target Injection

109.12

Adjusted Volume

42.0112

6

0 -----------------------------------------------------------------------------------------20
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Figure 9-8: Blood Plasma Concentration Curve for Mouse 20140728B-1 70/30 Stair
Step. With each observed data point (•), the 70% target (solid line), and the 30%
target (dashed line).
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9.3.3

Continuous Infusion

The final protocol, deemed successful, is demonstrated through two successful
injections profiles (Figure 9-10 and Figure 9-11).
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Figure 9-10: Injection phase blood plasma concentration curve for Mouse 201408040.
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Figure 9-11: Injection phase blood plasma concentration curve for Mouse 201408042.
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9.4

9.4.1

Discussion and Review o f Specifications

Equal Volumes
The equal volumes method was not expected to be meet specifications, but

potentially narrow the spread o f maximum blood plasma concentrations. It was based on
the idea that we were injecting different volumes in different mice and observing
different maximum concentrations; we should trying injecting the same volume to
observe the outcome. Table 9-1 shows the spread o f the data from this group, ranging
from 2.1-3.1 OD. This range o f data did not meet specifications and the next method was
attempted.
9.4.2

Step Injections
The 70/30 stair step shown in Figure 9-8 was created using a convoluted protocol

that was not able to attain the level o f precision desired. As demonstrated by the target
being five and a half OD and the observed maximum blood plasmas concentration being
closer to three and a half. The convoluted nature o f the injection scheme was filled with
problems, such as a difficult to follow protocol regarding the volume o f the 30 % step.
This particular mistake was made during the injection and caused the final target blood
plasma concentration to drop from 5.5-4.65 OD by not attempting to make up for the
previously lost concentration in the 70% step. The problems found in the protocol, and
ease o f mistakes (even by the person who created the protocol) lead to create a more
simple “stair step” injection pattern (shown in Figure 9-9). This injection method was
successful (and met specifications) in reaching the target blood plasma concentration of
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four OD. The idea o f discrete injections was abandoned for the creation o f the more
simple continuous infusion targeted injections.
9.4.3

Continuous Infusion
The continuous infusion method is successful for targeting o f maximum blood

plasma concentration. The initial plan where injection rate was 20 pL/min for the first
80% o f the injection and then slowed to ten microliters per minute caused the noise or
discontinuity seen around ten minutes in Figure 9-10 and Figure 9-11. Due to these
discontinuities, it is recommended to pick one injection rate (the current recommendation
is 15 pL/min) and use it throughout the entire injection. Table 9-3 outlines the summary
o f specifications and which methods were effective.

T able 9-3: Summary o f Specifications.
Specification
Achieve a reproducible maximum
blood plasma concentration ± 0.05
OD

Status
Met by both the "Stair Step" and the
‘‘Continuous Infusion” method. With the
Recommendation: use the “Continuous
Infusion" method with a set flow rate o f 15
pL/min.

CHAPTER 10
PROTOCOL UPDATES

The experiments discussed throughout this dissertation developed a set o f
recommendations on providing more reproducible experiments in a murine model. Each
chapter discusses some o f the lessons learned and how these lessons were turned into
specifications for future experiments. This chapter outlines some o f the more important
protocol recommendations that are omnipresent in the experimentation o f the O ’Neal
group.

10.1

Injection

The setup o f the catheter system for pre-clinical use can create a loss o f fluid that
is a large given the scale o f a mouse injection. When using the injection pump system to
give a specified volume to the mouse it is suggested to minimize the number o f times a
syringe is changed out. Each time a syringe is changed out some fluid is lost by dripping
out from around the blunt tip connection to the catheter. In a human injection, the loss o f
a few microliters from drips during syringe change would be negligible, but with the
small volumes injected for a mouse, it is proportionately large. For this reason the revised
recommendation for injection is to estimate the volume o f saline in the tubing prior to
animal catheterization, and add that “dead” volume o f saline to the volume o f intended
injection and set the syringe pump to the new total volume (injection volume combined
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with “dead” volume). When the syringe pump has moved the combined volume into the
animal this should minimize the loss o f nanoparticles and provide a more reproducible
injection. In addition, the use o f the same length o f catheter tubing (six inches) and
needles with the same gauge and length should improve the precision o f nanoparticle
delivery.

10.2
10.2.1

NanoTracker

Animal Heating
Animals with poor peripheral circulation are difficult to get NanoTracker signals

from, due to the location o f the probe on the tail. The use o f a deltaphase isothermal pad
or physitemp feedback heating pad is recommended. In addition to the heating pad, the
use o f space heaters to ensure the airflow around the mouse is 35-39°C will assist in
providing peripheral circulation for an adequate signal.
10.2.2

Data Collection and Analysis
To ensure the reproducible analysis o f NanoTracker data a series o f MATLAB

codes have been developed. These MATLAB codes ensure the basic data standards are
met (including: the heart rates from each channel should be ±20% o f the computed mean,
the ACamplitude should be greater than three millivolts and less than 100 millivolts, and
the standard deviation o f the optical density readings o f the averaged time should be less
than 0.03). A sample MATLAB code is shown in APPENDIX B: Sample MATLAB
processing code. This code does the following:
•

imports the raw data from a saved file

•

evaluates each line for the data standards (above)

•

ensures the entire time period (default o f five seconds) is considered good
data

•

removes the unnecessary lines o f data (the four duplicate lines o f the five
second time period)

•

creates a new array with only the filtered data

•

graphs the data (both averaged for a time point and each good data point)

•

provides the following (on the graph o f time point averaged data)
o

an exponential regression

o

area under the curve (by trapezoidal rule)

o

area under the first moment curve

o

the mean residence time

o

half-life (based off the exponential regression)

•

Saves the data files as excel spreadsheets

•

Exports the graphs as JPEG and MATLAB figure files

•

Can create a “WinBUGS import file”

10.3

Hatteras Blood Pressure System

The Hatteras blood pressure system should be started approximately 30 minutes
before the intended use to ensure the animal platform has ample time to warm up. This
need for the platform to be warm means the settings must be entered not just the machine
being switched on. The balloon should be replaced a minimum o f once a week, and
pressure tested each day. The high (150 mmHg) and low (50 mmHg) pressure calibration
should be performed a minimum o f every three days. The mouse tail should be held in

place manually or by restraint system during measurement. The mouse is unlikely to
remain motionless for the amount o f time needed and will require immobilization o f the
tail. A set o f typical system parameters is given in Table 10-1.

Table 10-1: Summary Hatteras Blood Pressure System Settings.
Parameter
Preliminary Cycles
Measurement Cycles
Movement Detection
Minimum Pulse Amplitude
Number o f Peaks
Minimum peaks
Maximum pressure
Pulse timeout
Measurement
Time between measurements
Systolic threshold
Signal below threshold
Time below
Diastolic threshold
Signal below
Time below
Temperature

Recommended Value
3
8
On
6
40
0.5
200
30 seconds
60 seconds
2.5 seconds
20
90
0.5
80
90
0.5
100-110

CHAPTER 11
CONCLUSIONS AND FUTURE WORK

A series o f protocol updates and recommendations have been presented. These
recommendations are made based on meeting specifications outlined in Table 1-1. The
specifications were developed from observed real-world problems in the original preclinical and clinical methods, some o f which are still in use today. These protocols have
been implemented in pre-clinical studies and are driving our work toward a set o f "‘best’7
practices for nanomedicine. This body o f work demonstrates the beginning o f a long road
o f improvements to pre-clinical protocols. Our industrial partner (Nanospectra
Biosciences, Inc.) currently conducting pre-clinical and clinical studies has not adopted
the protocol improvements made in this dissertation. Closing the gap between the
developed pre-clinical practices (in an academic setting) and pre-clinical and clinical
setting (in industry) is part o f future work that is necessary for a set o f best practices to
fully develop. The primary goal o f these recommendations is improved clinical
outcomes. The primary work toward improved clinical outcomes is developing through:
•

Making treatment decisions through observation o f clinical signs (real
time blood plasma concentration and rapid elemental analysis o f biopsied
tissue

•

Quantifying influential factors, and continuing to search for new factors
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•

Improved particle characterization (ensuring the solution is what you think
you are injecting through UV/vis and/or DLS)

•

Ensuring the proper dose is found circulating through real-time blood
plasma concentration readings

•

Acknowledging problems with the animal model and de-prioritizing
model specific problems (i.e. stop solving problems with no clinical
relevance, and focus on problems that can improve clinical outcomes)

•

Realize not all problems have been found yet and we need to continually
reevaluate for new methods o f improving clinical outcomes.

In advance o f the implementation o f industry standard popPK modeling
techniques, the NanoTracker and current MATLAB coding were able to create
individualized pk models. These individual one-compartment pk models are designed for
near-real-time clinical implementation. The personalized one-compartment models
provide the ability for comparison o f physiological responses to the treatment and allow
us to head toward personalized cancer treatments. The popPK models can assist NBI with
their ongoing pre-clinical and clinical trials, and provide useful starting point information
tailored to the patient (provided from the popPK models).
The protocols associated with the use o f the NanoTracker have been evaluated,
and modified as needed for use with PEGylated gold nanoshells and nanorods. The
protocol updates implemented in this work emphasize the ability to record data for post
processing that is more sophisticated. This sophistication includes the ability to
reproducibly enforce data quality standards and create graphs, currently with MATLAB.
The importance o f standardized data analysis and monitoring is found primarily when
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future protocols use these devices to inform clinical decisions in real time. Early
academic or pre-clinical studies have the luxury o f time for making decisions, but clinical
decisions will be made using this information in an urgent and life threatening climate.
The climate these decisions will be made in highlights the need for standardized and
easily interpreted results. The path toward data driven medicine will involve the
personalized one compartment modeling from real-time blood plasma monitoring, and
ability to observe tumor uptake metrics. The ability to collect tumor uptake data is
available through rapid elemental analysis.
The proposed rapid elemental analysis technique (EDXRF- used in this work)
allows for the quantitative analysis o f gold in animal tissues. With a focus on future
clinical implementation, elemental analysis will be required to be completed in under 12
hours. The current 12-hour window is based on timing o f currently implemented clinical
treatment protocols. This elemental analysis technique meets these requirements, and
continues to be used in our animal research due to its ease o f use and short turnaround
time. Additional quantitative studies would be required to fully validate the technique and
characterize the sources o f errors in the protocol prior to human clinical use.
Future work should build on the set o f one-compartment models to create a
desired blood plasma concentration curve. From the desired curve there is potential for
the implementation o f traditional electrical engineering controls methods [79] to attempt
to ensure a uniform blood plasma concentration curve. In future clinical settings, it will
be possible for the delivery o f nanoparticles to be different and contain new dosing
strategies to ensure optimization o f tumor uptake. The limitations o f our current murine
model only allow for one injection over a short period (limited by the time an animal is
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capable o f safely being under anesthesia), but clinical work can be conducted with longer
infusions (because human infusions can be given with larger variation). In addition to the
ability to create a more uniform blood plasma concentration curve from patient to patient,
the one-compartment models will be able to assist with the detection o f undesired
reactions (e.g. anaphylaxis). The use o f popPK models could be used to explore
individual variables from previous experiments for significant cofactors, and potentially
explore minor protocol differences between research groups using particles provided by
Nanospectra Biosciences, Inc. As future studies search for improving clinical outcomes,
it is important to remember the ideas, protocol updates, and specifications listed here are
a starting point. Some factors o f clinical importance may not have been discovered yet.

APPENDIX A
MOUSE BLOOD DRAW PROTOCOL

A .l

Theory

Blood draws taken from a mouse post injection o f nanoshells can be used to
measure the concentration o f circulating nanoshells. UV-Vis spectra o f the diluted blood
draws can be analyzed using Beer’s Law to separate extinction caused by the
oxyhemoglobin and nanoshells in the sample. This is done by observing the value at the
peak extinction wavelength for nanoshells and by using Eq. A -l:
Apeak

=
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+

e Hb

02^H

b
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Eq. A -l

Where A is the extinction at the peak wavelength, the e ’s are the extinction
coefficients for the two compounds o f interest (oxyhemoglobin(compound b) and
nanoshells(compound a) in this case) at the peak wavelength, and cns and cnb02 are the
concentrations nanoshells and Hb02. Note that we are using the extinction coefficient
for oxyhemoglobin because the blood samples have been exposed to air in the sampling
process. Therefore, we assume that the hemoglobin is fully oxygenated. Also note that
the extinction is pathlength dependent, but we assume that D is one centimeter.
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The concentration o f nanoshells in the sample can be expressed using Eq. A-2
n

_

A p e a k ~ ^ H b 0 2 £ Hb02

l NS —

A .1.1

£NS

•

c A-2
a
Eq.

Finding the Extinction Coefficients for Nanoshells
Since Beer’s Law expresses concentrations as moles/liter, we will examine the

nanoshells as if each one was one atom. Therefore, you will notice that the molarities of
nanoshells that are found in each sample are extremely low, but since they are such good
extinguishers o f light, their molar extinction coefficients will be extremely high. As
reported, batches o f nanoshells are manufactured to have a peak optical density o f 100 at
a wavelength between 760 and 820 nm. We will use an optical density o f 100 for 760
nm. The molar extinction coefficient is found using Eq. A-3:
A ns
£n s —

Eq. A-3

Cns

The concentration o f the nanoshells is reported as a number o f particles/ml. We
can find a molarity from Eq. A-4:
N P is
ml
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Blood Draws and Measurements
Once the extinction coefficient used in Eq. A-l & Eq. A-2 is found, we can inject

nanoparticles into a mouse, take blood samples, and examine them. The procedure for
taking a blood sample and analyzing it is as follows:
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1. Fill a micro-cuvette with 95 pi o f 10% Triton-X 100. Blank the spectrometer
using that micro-cuvette.
2. Heparinize a ten microliter pipette tip by sucking in five microliter o f heparin and
then releasing it leaving a layer o f heparin inside the tip
3. Obtain a five microliter blood sample using the heparinized tip and mix this with
the Triton-X in the cuvette
4. Scan this cuvette using the previously specified wavelengths (500-11 OOnm) and
record the extinction at 805 nm (Let’s say that is (igo5 )
5. Dilute the sample using 100 pi Triton-X and scan again and record the extinction
at 560 nm (p560)
6. The formula for optical density is as follows, in Eq. A-5:

0*805 " ( ^ ) * 2 * 84 0 ) * 20 = OD.

A.2

Eq. A-5

Adjustments

There will be an error in volume. To adjust for that multiply the final OD value by
1 .9 5
MS60

A.3

Calibration Curve/Typical Results

The spectra from blood draws taken from a mouse injected with nanoparticles can
be seen in Figure A -l, and the calibration curve is shown in Figure A-2.

138

Blood/NS Extinction Spectra
0.45

0.4
■£ 0.35

3

— Raw Blood

• 0.3

VI

JO

<

— 1.70E10 NP/mL

~ 0.25
£
0.2

— 1.36E10NP/mL

“ 0.15

— 1.02E10 NP/mL

c

4>
ra
u

“

0.1

6.8E9 NP/mL

0.05

— 3.40E9 NP/mL
750

650

950

850

1050

Note: C oncentrations in
N P/m L blood

W avelength

Figure A -l: Extinction spectra o f blood prior to (raw blood) and post (all other
spectra) injection. Note how the extinction at 760 nm increases greatly in comparison
to 940 nm and then begins to return to a spectrum more like that for raw blood.
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APPENDIX B
SAMPLE MATLAB PROCESSING CODE

The code below is an example o f the MATLAB processing code used to process
NanoTracker data. The purpose o f this particular code is to extract the data from the RES
Blockade experiments, process and create basic blood plasma concentration graphs, and
create the input files for WinBUGS.

clear all
clc
close all
mousenumber=input('enter mouse number as YYYYMMDD(CAGE)-(M01JSE):
lnjectionVolumel=input('enter the volume o f 100 OD NS or NR ');
InjectionVolume=lnjectionVolumel-75;
Mouse Weight=input('enter the weight o f the mouse ');
group=input(’enter the group number ','s');
Dose=(InjectionVolume)/(4.5*MouseWeight);
InjectionVolumeSTR=num2str(InjectionVolume);
MouseWeightSTR=num2str(MouseWeight);
DoseSTR=num2str(Dose);
nonmem(l,:)={'#ID','TIMH’,'AMT','R ATE YDV',’MDV','DOSE','WT'};
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nonmem(2,:)={'(D' ’()' Injection VolumeSTR 'O’ 7 T DoseSTR MouseWeightSTR};
alldata=zeros(l,24);
numberofdp=input('enter the number o f data points;');
countdp=l;
while countdp <=numberofdp
clear rawdatafile; clear raw data; clear timeresolveddata;
clear prelimiiltereddata; clear filtereddata
%PULL DATA FILE & TIME RESOLVE

filestarttime=input('Enter start time o f file

'.s');

rawdatafile=['C:\Users\ibmag_000\Documents\Dropbox\NCTSG Lab\Ravv
Data\C’arragcenan Eperiments\WinBUGSV,mousenumber,’V,filestarttime];
filestarttime=str2double(filestarttime);
rawdata=load(rawdatafile);
initialtime=rawdata( 1,10);
ti mereso Iveddata=rawdata;
timeresolveddata(:, 10)=rawdata(:, 10)-initialtime+filestarttime;

count=I;
count2=l;
length=size(rawdata);
length l=length( 1,1);
while count <= lengthl %the purpose o f this while loop is to remove rows with bad data
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%CHECK HR SI 1)1 V
clear X;
X=[timeresolveddata(count, 1) timeresolveddata(count,2) timeresolveddata(count,3)];
average=mean(X);
averageminus=average*0.8;
averageplus=average* 1.2;

if timeresolveddata(count, 1) <= averageplus
includeHR=l;
else
includeHR=0;
end
if timeresolveddata(count,2) <= averageplus
includeH Rl=l;
else
ineludeHRI=0;
end
if timeresolveddata(count,3) <= averageplus
includeHR2=l;
else
includeHR2=0;
end
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if averageminus <= timeresolveddata(count,l)
includeHR3=l;
else
includeHR3=0;
end
if averageminus <= timeresolveddata(count,2)
includeHR4=l;
else
includeHR4=0;
end
if averageminus <= timeresolveddata(count,3)
includeHR5=l;
else
includeHR5=0;
end
%( H lX 'k AC AMPLITUDE
if timeresolveddata(count,7) <=0.10
includeAC=l;
else
includeAC=0;
end
if timeresolveddata(count,8) <=0.10
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includeAC 1=1;
else
includeAC 1=0;
end
if timeresolveddata(count,9) <=0.10
includeAC2=l;
else
includeAC2=0;
end

if 0.003 <= timeresolveddata(count,7)
includeAC3=l;
else
includeAC3=0;
end
if 0.003 <= timeresolveddata(count,8)
includeAC4=l;
else
includeAC4=0;
end
if 0.003 <= timeresolveddata(count,9)
includeAC5=l;
else
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includeAC5=0;
end
% C I

I l i C K

S I D I . V

if timeresolveddata(count,13) <= 0.03
includeSTDEV=l;
else
includeSTDEV=0;
end
if timeresolveddata(count,16) <= 0.03
includeSTDEVl=l;
else
includeSTDEVl=0;
end

INCLUDE=includeHR*includeHRl*includeHR2*includeHR3*includeHR4*includeHR5
*includeSTDEV*includeSTDEVl*includeAC*includeACl*includeAC2*includeAC3*in
cludeAC4*includeAC5;

if INCLUDE == 1
prelimfiltereddata(count2,:)=timeresolveddata(count,:);
count2=count2+l;
else
end
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count=count+l;
end

%REMOVE DUPLICATE LINES
count=3;
count 1= 1;
length2=size(prelimfiltereddata);
Iength3=length2( 1,1 )-2;
while count <= length3 % r e m o v e du p lic a te values
‘.’.'.EXTRACT BY STDEV I
if prelimfi!tereddata(count, 13)== prelimfiltereddata(count+2,13);
includeplustwol=l;
else
includeplustwo I =0;
end

if prelimfiltereddata(count, 13)== prelimfiltereddata(count-2,13);
inc ludem inustwo 1=1;
else
includeminustwol=0;
end

INCLUDE 1=includeplustwo 1*includeminustwo 1;
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if INCLUDE 1 ~=0
fi ltereddata(count 1,: )=prel imfi ltereddata(count,:);
count l=count 1+1;
else
end
eount=count+l;
end
numberofgooddatapoints=size(fiItereddata);

averagedata(countdp, 1)=mean(filtereddata(:, 10)); %time
averagedata(countdp,3)=mean(filtereddata(:, 18)); %optical density
averagedata(countdp,2)=numberofgooddatapoints(l,l); %nuinber o f points being
averaged

alldata=[alldata;filtereddata];

TimeSTR=num2str(averagedata(countdp, 1));
OD_STR=num2str(averagedata(countdp,3));

nonmem(countdp+2,:)={'!□' TimeSTR '()’ 'O' OD STR 'O' DoseSTR MouseWeightSTR};

countdp=countdp+1;
clear T imeSTR
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clear OD SIR
end

%Kxponential Regression
mdl=@(a,x)(a( 1)*exp(-a(2)*x));
a0=[7;0.004];
beta=n Iin fi t( averagedata(:, 1),averagedata(:,3),mdl,a0);
xrange=0:0.01:1030;
uganda=mdl(beta,xrange);
averagedata(:,4)=mdl(beta,averagedata(:, 1));
r=corr2(averagedata(:,3),averagedata(:,4));
rsquarred=rA2;
halflife=log(.5)/-beta(2,1);

°i)Calculate ALJC
datal= [0 0 averagedata(l,3) 0];
data2=[datal ;averagedata];
data2(:,5)=data2(:, 1).!(!data2(:,3);
AUC=trapz(data2(:, 1),data2(:,3));
AUMC=trapz(data2(:, 1),data2(:,5));
MRT=AUMC/AUC;
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AUCs=num2str(AUC);
AUMCs=num2str(AUMC);
MRTs=num2str(MRT);

figl=figure(l);
MM=num2str(filtereddata( 1,20));
DD=num2str(filtereddata( 1,21));
YYYY=num2str(filtereddata( 1,19));
doe=[MM,'/',DD,7',YYYY];
plot(averagedata(:,l),averagedata(:,3),'b.',xrange,Uganda,'"-.')
titlestr=['CARRAGEHNAN Mouse ’,mousenumber,’ Date o f Experiment: \doe];
title(titlestr);
betaA=num2str(beta( 1,1));
betaB=num2str(beta(2,1));
halflifestr=num2str(halflife);
rsquarred2=num2str(rsquarred);
annotationstr{ 1}=['y=',betaA,'*exp(-’,betaB,'*t) rA2=',rsquarred2,’ Half
L ife-,halflifestr,'m ias’];
annotationstr{2}=['AUC=',AUCs,'OD*inin. AUMC=',AUMCs,'0D*niinA2
M RT=',MRT s,'m in s'];
text(25,0.5,annotationstr)
legend('data','curve fit')
xlabel('Time (mins)');
ylabel('Concentration (Optical Density)');
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axis([0 400 0 4.5]);

fig2=figure(2);
plot(alldata([2:end],10),alldata([2:end],18),'b.')
titlestr=['CARRAGEENAN Mouse ',mousenumber,' Date o f Experiment: ’,doe];
title(titlestr);
xIabel('Time (mins)');
ylabel('Coneentration (Optical Density)');
axis([0 400 0 4.5]);

savestr=['C:U sers ibmag 000 Documents Dropbox NCTSG
Lab\Carrageenan\Data\WinBUGS\Group ’,group,"‘.Group’,group,'Mouse',mousenumber];
%........... Save Average Data Sheet and Figures
saveas(fig 1,[savestr,'averagedata']);
saveas(fig 1,[savestr,'averagedata.jpg']);
header={’Time','Number o f PointsVAverage OD',’Curve Fit OD at time'};
xlswrite([savestr,'averagedata'],header,'sheet I');
xlswrite([savestr,'averagedata'],averagedata,'sheet l','A2’);
%........... Save All Data Sheet and Figures
alldataheader={'UR I ','HR2','I IR3','DC 1','DC 2','DC3','AC I ','AC2','AC3','TlMf ','R 1','A V
(i R 1','STDBV R 1','R2','A VG R2',’STDFV
R2’,'SP02','OD’,'YEAR','MONFH','DAY','HOUR','MIN','SBC'};
saveas(fig2,[savestr,'alldata']);
saveas(fig2,[savestr,'al ldata.jpg']);
xlswrite([savestr,'alldata'],alldata,'sheet 1','A I');
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xlswrite([savestr,’alldata’],alldataheader,'sheet I ','A 1');
%—.......Save nonmem
xlswrite([savestr,'nonmem'],nonmem,’sheet 1’,'A 1’);
beep

APPENDIX C
2,2,2-TRIBROMOETHANOL (AVERTIN)

Avertin is useful for use in procedures where immobilization is less than 20
minutes and with no significant pain or distress. Avertin should provide good skeletal
muscle relaxation and a moderate degree o f respiratory depression.

C .l

Contraindication

Repeated administrations o f avertin are contraindicated.

Do NOT inject intravenous, animal death would be expected within minutes.

C.2

Materials

2,2,2-tribromoethanol (Sigma-Aldrich T48402)
2-Methyl-2-Butanol (Alfa Aesar A18304)

C.3

Avertin Stock Solution

Mix:
1. 15 g 2,2,2-tribromoethanol
2.

15.5 mL 2-Methyl-2-Butanol

3. Mix overnight in dark (amber) bottle at room temperature, (be sure to use clean
stir bar)
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The stock solution has a shelf life o f six months when stored wrapped in foil in a
dark cabinet at room temperature. The following information MUST be on the outside o f
the bottle and the box the bottle is stored in: Solution, Expiration date, grams o f 2,2,2tribromoethanol and lot number, mL 2-Methyl-2-Butanol and lot number.

C.4

Avertin Working Solution

Mix:
1. 0.1 mL Avertin Stock Solution
2. 7.9 mL 0.9% Sterile Saline
3. Mix in a dark bottle and store overnight
4. Filter sterilize with 0.22 pm filter, label and store at four to six degrees Celsius.
Working solution has a shelf life o f six months if unopened.
Once the working solution has been opened it has a shelf life o f one week.
All containers o f working solution must be labeled with the following
information: Solution, Expiration date (once opened), Date o f sterilization, Your Initials,
mL Avertin stock solution, mL saline.

C.5

Animal Injection

Avertin is given via intraperitoneal (IP) injection o f Avertin Working Solution at
the following dose:
Normal injection for slow particle infusion: 25 pL/g body weight.
Normal injection for standard immobilization: 20 pL/g body weight.

APPENDIX D
USE OF REAL-TIME PHARMACOKINETICS
TO PREDICT TUMOR UPTAKE

MOUM 201 1 ’ 104A-S ;C*K?up 1*1 0*t* 0< fciptmwt* tV tU W U

TOO

<00

800

800

1000

121X

7m * ‘irwaj

M «*»e20nf!04AS<Graup t»< D«t» of £xp*urrwr«
(Ml*

curved

I;
1 5r

y-4 7801*«pC-0 002226H f*-0 674%
H#lfUte*Tt1 S t 5 m « . AUC«1824 039/OD'rmn
400

BOO

800

<000

120f

Tim* {frown

Figure D -l: Charts for mouse 20111104A-5 (Group A- 21.08PPM). Top: All Data,
Bottom: Averaged Data.
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APPENDIX E
CONTINUATION OF DATA FOR CHAPTER 7:
OBSERVATION OF COFACTORS ON
PREDICTION OF TUMOR UPTAKE

— ----

s-------

*
% ai

0 15-.

J# i

soy
Turner

M c^ 7 C O » 2 1 C ^ l O tfeOiEwwneni « I . O T 3

y«1^50rexpi-<500t»23*!i
rJ-0 8^756 m t ufe»3SS 24im«*
AUC> 127 &4?SOD*mr>. AUMC»7401.4473COW
MftT*W i3M n*»

U 5!'
j__

g

S

0

CUMPftt
.......... ..

* ?!

100

200

300

400

400

803
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APPENDIX F
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
APPROVAL LETTER

IN S T IT U T IO N A L A N IM A L C A R E A N D U S E C O M M IT T E E
L o u isian a Tech U n iv e rsity

25 October 2011
Dr. Patrick O ’Neal, Ph.D.
Biomedical Engineering
Louisiana Tech University
Campus Box # 58
Dear Dr. O ’Neal:
The Louisiana Tech University’s Institutional Animal Care and Use Committee (IACUC) met
17 October and approved your amended protocol entitled:

on

Vanopartiele Tracking For Cancer Therapy
The committee members feel that the transport of mice from Houston that have been inoculated
with cancer cells is appropriate, and in keeping with your previous protocols. Please make sure
that the animals are in a transport box with adequate water and that the vehicle be air-conditioned
at all times so that the animals will not become dehydrated or overheated.
You and the students have been approved for a limit of 50 animals in this initial study beginning
1 November 2011. Please remember that you are required to keep adequate and accurate records
of all procedures, results, and the number of animals used in this protocol. You are required to
provide a progress report each year by 1 October. If the project should need to be extended
beyond 31 October 2014, the third year, you will be required to submit a new protocol. Any
changes you need to make in the protocol before the termination date must be submitted to the
IACUC on the amendment form for approval before implementation.
Keep for your research records and results for three years after termination of the project. These
records must be available for review by the IACUC or state and federal ammat use agencies.
Each year by 31 October you will be required to complete a summary of number o f animals used
in this protocol used for the United States Agricultural Agency (USDA). Note that failure to
follow this protocol as approved may result in the termination o f research. If you have any
questions please call me at 318-243-07% or via e-mail at igspauld'qilatech.edu.
Sincerely.

James G. Spaulding, Chair
Louisiana Tech University IACUC
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